Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS
BACKGROUND
The present invention relates to piperidine derivatives useful as
selective CCR5 antagonists, pharmaceutical compositions containing the
compounds, and methods of treatment using the compounds. The
invention also relates to the use of a combination of a CCRS antagonist of
this invention and one or more antiviral or other agents useful in the
treatment of Human Immunodeficiency Virus (HIV). The invention further
relates to the use of a CCR-5 antagonist of this invention, alone or in
combination with another agent, in the treatment of solid organ transplant
rejection, graft v. host disease, arthritis, rheumatoid arthritis,
inflammatory
bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple
sclerosis.
The global health crisis caused by HIV, the causative agent of
Acquired Immunodeficiency Syndrome (AIDS), is unquestioned, and while
recent advances in drug therapies have been successful in slowing the
progression of AIDS, there is still a need to find a safer, more efficient,
less
expensive way to control the virus.
It has been reported that the CCR5 gene plays a role in resistance
to HIV infection. HIV infection begins by attachment of the virus to a target
cell membrane through interaction with the cellular receptor CD4 and a
secondary chemokine co-receptor molecule, and proceeds by replication
and dissemination of infected cells through the blood and other tissue.
There are various chemokine receptors, but for macrophage-tropic HIV,
believed to be the key pathogenic strain that replicates in vivo in the early
stages of infection, the principal chemokine receptor required for the entry
of HIV into the cell is CCRS. Therefore, interfering with the interaction
between the viral receptor CCRS and HIV can block HIV entry into the cell.
The present invention relates to small molecules which are CCR5
antagonists.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-2-
CCR-5 receptors have been reported to mediate cell transfer in
inflammatory diseases such as arthritis, rheumatoid arthritis, atopic
dermatitis, psoriasis, asthma and allergies, and inhibitors of such receptors
are expected to be useful in the treatment of such diseases, and in the
treatment of other inflammatory diseases or conditions such as
inflammatory bowel disease, multiple sclerosis, solid organ transplant
rejection and graft v. host disease.
Related piperidine derivatives which are muscarinic antagonists
useful in the treatment of cognitive disorders such as Alzheimer's disease
are disclosed in US patents 5,883,096; 6,037,352; 5,889,006; 5,952,349;
and 5,977,138.
A-M. Vandamme et al., Antiviral Chemistry & Chemotherapy, 9:187-
203 (1998) disclose current clinical treatments of HIV-1 infections in man
including at least triple drug combinations or so-called Highly Active
Antiretroviral Therapy ("HAART"); HAART involves various combinations of
nucleoside reverse transcriptase inhibitors ("NRTI"), non-nucleoside
reverse transcriptase inhibitors ("NNRTI") and HIV protease inhibitors ("PI")
In compliant drug-naive patients, HAART is effective in reducing mortality
and progression of HIV-1 to AIDS. However, these multidrug therapies do
not eliminate HIV-1 and long-term treatment usually results in multidrug
resistance. Development of new drug therapies to provide better HIV-1
treatment remains a priority.
SUMMARY OF THE INVENTION
The present invention relates to the treatment of HIV comprising
administering to a human in need of such treatment an effective amount of
a CCR5 antagonist represented by the structural formula I:
Ria
R, X R~s
N R1 Ris
~l
N ~O
R2 I
or a pharmaceutically acceptable salt thereof, wherein
X is -C(R~3)2-, -C(R13)(R19)_, _C(O)_, _O_, -NH-, -N((C1-C6)alkyl)-,
OR3 CH2-(C1-C5)alkyl-R3 NOR4 O-(C~-C6)alkyl CH-(C~-C6)alkyl
-CR'3- ~ CR'3- , C ~ -CR~3- , C
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-3-
O-C(O)-(C 1-C6)alkyl O-C(O)-O-(C ~-C6)alkyl O-C(O)-NH-(C ~-C6)alkyl
_CRis_ _CR~s- -CR~s_
O-C(O)-N((C1-C6)alkyl)2 NR5-C(O)-(C1-C6)alkyl
-CR'3- ~ -CR'3-
NR5-C(O)-O-(C1-C6)alkyl NR5-C(O)-NH-(C1-C6)alkyl
-CR~3- ~ -CR~3-
NR5-C(O)-N-((C1-C6)alkyl)2 C(O)-(C1-C6)alkyl
-CR~3- or -N-
R is R6-phenyl, R6-pyridyl, R6-thiophenyl or R6-naphthyl;
R~ is hydrogen, C1-C6 alkyl or C2-C6 alkenyl;
R2 is R~, R8, Rg-phenyl; R~, R8, R9-substituted 6-membered
heteroaryl; R~, R8, R9-substituted 6-membered heteroaryl N-oxide;
R», R> >-substituted 5-membered heteroaryl; naphthyl; fluorenyl;
R1~ Ri2 R»
-C ~ ~ -C-heteroaryl
diphenylmethyl R'8 or R1a ;
R3 is R6-phenyl, R6-heteroaryl or R6-naphthyl;
R4 is hydrogen, C1-C6 alkyl, fluoro-C~-Cg alkyl, cyclopropylmethyl,
-CH2CH20H, -CH2CH2-O-(C~-C6)alkyl, -CH2C(O)-O-(C~-C6)alkyl,
-CH2C(O)NH2, -CH2C(O)-NH(C1-C6)alkyl or -CH2C(O)-N((C1-C6)alkyl)2;
RS and R> > are independently selected from the group consisting of
hydrogen and (C~-C6)-alkyl;
R6 is 1 to 3 substituents independently selected from the group
consisting of hydrogen, halogen, C~-C6 alkyl, Ci-C6 alkoxy, -CF3, CF30-,
CH3C(O)-, -CN, CH3S02-, CF3S02-, R~4-phenyl, R~4-benzyl,
CH3C(=NOCH3)-, CH3C(=NOCH2CH3)-, o ~ I So2 , -NH2, -NHCOCF3,
-NHCONH(Ci-C6 alkyl), -NHCO(C~-C6 alkyl), -NHS02(C~-C6 alkyl),
0
~l
-N X
5-membered heteroaryl and ~ , wherein X is -O-, -NH- or -N(CH3)-;
R~ and R$ are independently selected from the group consisting of
(C~-Cg)alkyl, halogen, -NRZ°Rz', -OH, -CF3, -OCHg, -O-acyl, and -OCF3;
R9 is R', hydrogen, phenyl, -N02, -CN, -CH2F, -CHF2, -CHO,
-CH=NOR2°, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl,
-N(R2°)CONR2'R22, -NHCONH(chloro-(C,-C6)alkyl), -NHCONH((C3-C,o)-
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-4-
cycloalkyl(C,-Cs)alkyl), -NHCO(C,-Cs)alkyl, -NHCOCF3, -NHS02N((C,-
Cs)alkyl)2, -NHS02(C,-Cs)alkyl, -N(S02CF3)2, -NHC02(C,-Cs)alkyl, Cs-C1o
cycloalkyl, -SR23, -SOR23, -SO2R23, -S02NH(C,-Cs alkyl), -OS02(C,-
Cs)alkyl, -OS02CF3, hydroxy(C,-Cs)alkyl, -CON R2°R2', -CON(CH2CH2-
O-
CH3)2,
-OCONH(C,-Cs)alkyl, -C02R2°, -Si(CH3)3 or -B(OC(CH3)2)2;
R» is (C~-C6)alkyl, -NH2 or R~2-phenyl;
R12 is 1 to 3 substituents independently selected from the group
consisting of hydrogen, (C~-C6) alkyl, -CF3, -C02R2°, -CN, (C,-
Cs)alkoxy
and halogen;
R~3, R14, R~5 and R~6 are independently selected from the group
consisting of hydrogen and (Ci-C6)alkyl;
Rj~ and R~8 are independently selected from the group consisting of
hydrogen and C~-C6 alkyl, or Rig and R18 together are a C2-C5 alkylene
group and with the carbon to which they are attached form a spiro ring of 3
to 6 carbon atoms;
R'9 is R6-phenyl, R6-heteroaryl, R6-naphthyl, C3-C,o cycloalkyl, (C3-
C,°)cycloalkyl(C,-Cs)alkyl or (C,-Cs)alkoxy(C,-Cs)alkyl;
R2°, R2' and R22 are independently selected from the group
consisting of H and C,-Cs alkyl; and
R23 is C,-Cs alkyl or phenyl.
Preferred are compounds of formula I wherein R is R6-phenyl,
especially wherein R6 is a single substituent, and especially wherein the R6
substituent is in the 4-position. Also preferred are compounds of formula I
wherein R~3, R~4, R~5 and R~6 are each hydrogen or methyl, especially
hydrogen. Also preferred are compounds of formula I wherein X is
-CHOR3, -C(R'3)(R'9)- or -C(=NOR4)-; a preferred definition for R3 is
pyridyl, especially 2-pyridyl, a preferred definition for R4 is (C~-C6)alkyl,
especially methyl, ethyl or isopropyl, a preferred definition for R'3 is
hydrogen, and a preferred definition for R'9 is R6-phenyl. For compounds of
formula I, R~ is preferably (C~-C6)alkyl, especially methyl.
In compounds of formula I, R2 is preferably R~, R8, R9-phenyl,
R~, R8, R9-pyridyl or an N-oxide thereof, or R~, R8, R9-pyrimidyl. When R2
is pyridyl, it is preferably 3- or 4-pyridyl, and when pyrimidyl, it is
preferably
5-pyrimidyl. The R~ and R8 substituents are preferably attached to carbon
ring members adjacent to the carbon joining the ring to the rest of the
molecule and the R9 substituent can be attached to any of the remaining
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-5-
unsubstituted carbon ring members, for example as shown in the following
structures:
R~~ Ra R~ ~ R8 R~ ~ R8 R~~ Ra
y ~N~~ R9 Nv~ and IN
Rs ~ , Rs Rs
Preferred R~ and R8 substituents are: (C~-C6)alkyl, especially
methyl; halogen, especially chloro; and -NH2. A preferred R9 substituent
is hydrogen.
Also claimed are novel CCR5 antagonist compounds represented
by the structural formula II
Rya
a~Xa R~5
Ris
~l
N ~O
R2 I I
or a pharmaceutically acceptable salt thereof, wherein
Xa is _C(R13)2_ _C(R13)(R19)_ _C(O)_, _O_, -NH-, -N((C1-C6)alkyl)-,
OR3 CH2-(C~-C5)alkyl-R3 NOR4 O-(C1-C6)alkyl CH-(C~-C6)alkyl
-CR'3- , -CR'3- C , CR~3 , C ,
O-C(O)-(C ~-C6)alkyl O-C(O)-O-(C ~-C6)alkyl O-C(O)-NH-(C 1-C6)alkyl
~5 -CR~3- ~-CR13- ~-CR13-
O-C(O)-N((C1-C6)alkyl)2 NR5-C(O)-(C1-C6)alkyl
-CR~3- ' -CR'3-
NR5-C(O)-O-(C1-C6)alkyl NR5-C(O)-NH-(C~-C6)alkyl
-CR'3- ' -CR~3-
NR5-C(O)-N-((C1-C6)alkyl)2 C(O)-(C~-C6)alkyl
-CR'3- or -N-
Ra is R6a-phenyl, R6a-pyridyl, R6a-thiophenyl or R6-naphthyl;
R~ is hydrogen, C~-C6 alkyl or C2-C6 alkenyl;
R2 is R~, R8, R9-phenyl; R~, R8, R9-substituted 6-membered
heteroaryl; R~, R8, R9-substituted 6-membered heteroaryl N-oxide;
R», R> >-substituted 5-membered heteroaryl; naphthyl; fluorenyl;
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-6-
R17 12 R17
_ R
-C ~ ~ -C-heteroaryl
diphenylmethyl R1s or R1s
R3 is R~ ~-phenyl, pyridyl, pyrimidyl, pyrazinyl or thiazolyl;
R4 is hydrogen, C~-Cg alkyl, fluoro-C~-C6 alkyl, cyclopropylmethyl,
-CH2CH20H, -CH2CH2-O-(C~-C6)alkyl, -CH2C(O)-O-(C1-C6)alkyl,
-CH2C(O)NH2, -CH2C(O)-NH(C~-Cg)alkyl or -CH2C(O)-N((Ci-C6)alkyl)2;
R5 and R1 ~ are independently selected from the group consisting of
hydrogen and (C~-Cg)-alkyl;
Rsa is 1 to 3 substituents independently selected from the group
consisting of hydrogen, halogen, -CF3, CF30-, -CN, -CF3SOz-, R'2-phenyl,
O
-N X
-NHCOCF3, 5-membered heteroaryl and ~ , wherein X is -O-, -NH-
or -N(CH3)- ;
R6 is independently selected from the group consisting of R6a and
CH3S02-;
R~ and R8 are independently selected from the group consisting of
(Ci-C6)alkyl, halogen, -NR2°Rz' , -OH, -CF3, -OCH3, -O-acyl, and -OCF3;
R9 is R', hydrogen, phenyl, -N02, -CN, -CH2F, -CHF2, -CHO,
-CH=NOR2°, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl,
-N(R2°)CONR21R22, -NHCONH(chloro-(C1-C6)alkyl), -NHCONH((C3-C1o)-
cycloalkyl(C1-C6)alkyl), -NHCO(C1-Cs)alkyl, -NHCOCF3, -NHS02N((C1-
C6)alkyl)2, -NHS02(C1-Cs)alkyl, -N(S02CF3)2, -NHC02(Ci-C6)alkyl, C3-C,o
cycloalkyl, -SR23, -SOR23, -SO2R23, -S02NH(C1-Cs alkyl), -OS02(C1-
Cs)alkyl, -OS02CF3, hydroxy(C1-C6)alkyl, -CON R2°R21, -CON(CH2CH2-
O-
CH3)2,
-OCONH(C1-Cs)alkyl, -C02R2°, -Si(CH3)3 or -B(OC(CH3)2)2;
R» is (C~-C6)alkyl, -NH2 or R12-phenyl;
R~2 is1 to 3 substituents independently selected from the group
consisting of hydrogen, (C~-C6) alkyl, -CF3, -C02R2°, -CN, (C1-
C6)alkoxy
and halogen;
R13 R14 Ri5 and R~6 are independently selected from the group
consisting of hydrogen and (C1-C6)alkyl;
R» and R1$ are independently selected from the group consisting of
hydrogen and C1-C6 alkyl, or R» and R~$ together are a C2-C5 alkylene
group and with the carbon to which they are attached form a spiro ring of 3
to 6 carbon atoms;
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
_7_
R'9 is R6-phenyl, R6-heteroaryl, R°-naphthyl, C3-C,o cycloalkyl,
(C3-
C1°)cycloalkyl(C,-C6)alkyl or (C,-C6)alkoxy(C~-C6)alkyl;
R2°, R2' and R22 are independently selected from the group
consisting of H and C,-Cs alkyl; and
R23 is C,-Cs alkyl or phenyl; or
(2):
Xa is -C(R~3)(R~9)-, -C(O)-, -O-, -NH-, -N((C~-Cg)alkyl)-,
OR3 CH2-(C~-C5)alkyl-R3 NOR4a O-C(O)-(C 1-C6)alkyl
-CR13- , -CR'3- , C , -CR~3- ,
O-C(O)-(C ~-C6)alkyl O-C(O)-NH-(C ~-C6)alkyl
-CR~3- ~ -CR~3- ,
O-C(O)-N((C~-C6)alkyl)2 NR5-C(O)-(C1-C6)alkyl
-CR'3- ~ -CR'3-
NR5-C(O)-O-(C ~-C6)alkyl NR5-C(O)-NH-(C 1-C6)alkyl
-CR~3- ' -CR'3-
NR5-C(O)-N-((C1-C6)alkyl)2 C(O)-(C~-C6)alkyl
-CR13- or -N-
Ra is R6b-phenyl, R6b-pyridyl or R6b-thiophenyl;
R4a is fluoro-C~-C6 alkyl, cyclopropylmethyl, -CH2CH20H,
-CH2CH2-O-(Ci-C6)alkyl, -CH2C(O)-O-(Ci-C6)alkyl, -CH2C(O)NH2, -
CH2C(O)-NH-(C1-C6)alkyl or -CH2C(O)-N((C~-C6)alkyl)2;
R6b is CHgS02-; and
R1, R2, R3, R5, R~ 4, R~ 5, R~ 6 and R19 are as defined in (1 ).
Preferred are compounds of formula II(1) wherein Ra is R6a-phenyl,
especially wherein R6a is a single substituent, and especially wherein the
R6a substituent is in the 4-position. Also preferred are compounds of
formula II(1 ) wherein Xa is -CHOR3, -C(R'3)(R'9)- or -C(=NOR4)-; a
preferred definition for R3 is pyridyl, especially 2-pyridyl, a preferred
definition for R4 is (C1-C6)alkyl, especially methyl, ethyl or isopropyl, a
preferred definition for R'3 is hydrogen, and a preferred definition for R'9
is
R6-phenyl. For compounds of formula II(1), R~ is preferably (C1-Cg)alkyl,
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
_g-
especially methyl. Also for compounds of formula II(1 ), R~4, R15 and R~6
are preferably hydrogen.
Preferred are compounds of formula II(2) wherein Ra is R6b-phenyl,
especially wherein R6b is a single substituent, and especially wherein the
R6b substituent is in the 4-position. Also preferred are compounds of
formula II(2) wherein Xa is -CHOR3, -C(R'3)(R'9)- or -C(=NOR4a)-; a
preferred definition for R3 is pyridyl, especially 2-pyridyl, preferred
definitions for R4a are cyclopropylmethyl and trifluoroethyl, a preferred
definition for R'3 is hydrogen, and a preferred definition for R'9 is R6-
phenyl.
For compounds of formula II(2), R~ is preferably (Ci-Cg)alkyl, especially
methyl. Also for compounds of formula II(2), R~4, R15 and R~6 are
preferably hydrogen.
In compounds of formula II(1 ) and (2), R2 is preferably R~, R8, R9-
phenyl; R~, R8, R9-pyridyl or an N-oxide thereof; or R~, R8, R9-pyrimidyl.
When R2 is pyridyl, it is preferably 3- or 4-pyridyl, and when pyrimidyl, it
is
preferably 5-pyrimidyl. The R~ and R8 substituents are preferably attached
to carbon ring members adjacent to the carbon joining the ring to the rest of
the molecule and the R9 substituent can be attached to any of the
remaining unsubstituted carbon ring members as shown above for
compounds of formula I. Preferred R~ and R8 substituents for compounds
of formula II are: (C~-C6)alkyl, especially methyl; halogen, especially
chloro; and -NH2; a preferred R9 substituent is hydrogen.
Another aspect of the invention is a pharmaceutical composition for
treatment of HIV comprising an effective amount of a CCR5 antagonist of
formula (I in combination with a pharmaceutically acceptable carrier.
Another aspect of the invention is a pharmaceutical composition for
treatment of solid organ transplant rejection, graft v. host disease,
arthritis,
rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis,
psoriasis, asthma, allergies or multiple sclerosis comprising an effective
amount of a CCR5 antagonist of formula II in combination with a
pharmaceutically acceptable carrier.
Yet another aspect of this invention is a method of treatment of HIV
comprising administering to a human in need of such treatment an effective
amount of a CCR5 antagonist compound of formula II. Another aspect of
the invention is a method of treatment of solid organ transplant rejection,
graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel
disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-g_
comprising administering to a human in need of such treatment an effective
amount of a CCR5 antagonist compound of formula I or II.
Still another aspect of this invention is the use of a CCRS antagonist
of formula I or II of this invention in combination with one or more antiviral
or other agents useful in the treatment of Human Immunodeficiency Virus
for the treatment of AIDS. Still another aspect of this invention is the use
of
a CCRS antagonist of formula I or II of this invention in combination with
one or more other agents useful in the treatment of solid organ transplant
rejection, graft v. host disease, inflammatory bowel disease, rheumatoid
arthritis or multiple sclerosis. The CCR5 and antiviral or other agents which
are components of the combination can be administered in a single dosage
form or they can be administered separately; a kit comprising separate
dosage forms of the actives is also contemplated.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the following terms are used as defined below
unless otherwise indicated.
Alkyl (including the alkyl portions of alkoxy, alkylamino and
dialkylamino) represents straight and branched carbon chains and contains
from one to six carbon atoms.
Alkenyl represents C2-C6 carbon chains having one or two
unsaturated bonds, provided that two unsaturated bonds are not adjacent
to each other.
Substituted phenyl means that the phenyl group can be substituted
at any available position on the phenyl ring.
Acyl means a radical of a carboxylic acid having the formula
alkyl-C(O)-, aryl-C(O)-, aralkyl-C(O)-, (C3-C~)cycloalkyl-C(O)-, (C3-
C~)cycloalkyl-(C~-Cg)alkyl-C(O)-, and heteroaryl-C(O)-, wherein alkyl and
heteroaryl are as defined herein; aryl is R12-phenyl or R~2-naphthyl; and
aralkyl is aryl-(C~-Cg)alkyl, wherein aryl is as defined above.
Heteroaryl represents cyclic aromatic groups of 5 or 6 atoms or
bicyclic groups of 11 to 12 atoms having 1 or 2 heteroatoms independently
selected from O, S or N, said heteroatom(s) interrupting a carbocyclic ring
structure and having a sufficient number of delocalized pi electrons to
provide aromatic character, provided that the rings do not contain adjacent
oxygen and/or sulfur atoms. For 6-membered heteroaryl rings, carbon
atoms can be substituted by R~, R8 or R9 groups. Nitrogen atoms can
form an N-oxide. All regioisomers are contemplated, e.g., 2-pyridyl, 3-
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-10-
pyridyl and 4-pyridyl. Typical 6-membered heteroaryl groups are pyridyl,
pyrimidinyl, pyrazinyl, pyridazinyl and the N-oxides thereof. For 5-
membered heteroaryl rings, carbon atoms can be substituted by R1~ or R~1
groups. Typical 5-membered heteroaryl rings are furyl, thienyl, pyrrolyl,
thiazolyl, isothiazolyl, imidazolyl, pyrazolyl and isoxazolyl. 5-Membered
rings having one heteroatom can be joined through the 2- or 3- position; 5-
membered rings having two heteroatoms are preferably joined through the
4-position. Bicyclic groups typically are benzo-fused ring systems derived
from the heteroaryl groups named above, e.g. quinolyl, phthalazinyl,
quinazolinyl, benzofuranyl, benzothienyl and indolyl.
Preferred points of substitution for 6-membered heteroaryl rings at
R2 are described above. When R2 is a 5-membered heteroaryl group, the
R» and R~ ~ substituents are preferably attached to carbon ring members
adjacent to the carbon joining the ring to the rest of the molecule, and R> >
is preferably alkyl; however, if a heteroatom is adjacent to the carbon
joining the ring to the rest of the molecule (i.e., as in 2-pyrrolyl), R» is
preferably attached to a carbon ring member adjacent to the carbon joining
the ring to the rest of the molecule.
Halogen represents fluoro, chloro, bromo and iodo.
Fluoro(C~-Cg)alkyl represents a straight or branched alkyl chain
substituted by 1 to 5 fluoro atoms, which can be attached to the same or
different carbon atoms, e.g., -CH2F, -CHF2, -CF3, F3CCH2- and -CF2CF3.
A therapeutically effective amount of a CCRS antagonist is an
amount sufficient to lower HIV-1-RNA plasma levels.
One or more, preferaby one to four, antiviral agents useful in anti-
HIV-1 therapy may be used in combination with a CCR5 antagonist of the
present invention. The antiviral agent or agents may be combined with the
CCRS antagonist in a single dosage form, or the CCR5 antagonist and the
antiviral agent or agents may be administered simultaneously or
sequentially as separate dosage forms. The antiviral agents contemplated
for use in combination with the compounds of the present invention
comprise nucleoside and nucleotide reverse transcriptase inhibitors, non-
nucleoside reverse transcriptase inhibitors, protease inhibitors and other
antiviral drugs listed below not falling within these classifications. In
particular, the combinations known as HAART are contemplated for use in
combination with the CCR5 antagonists of this invention.
The term "nucleoside and nucleotide reverse transcriptase inhibitors"
("NRTI" s) as used herein means nucleosides and nucleotides and
CA 02371587 2005-05-05
-11-
analogues thereof that inhibit the activity of HIV-1 reverse transcriptase,
the enzyme
which catalyzes the conversion of viral genomic HIV-1 RNA into proviral HIV-1
DNA.
Typical suitable NRTIs include zidovudine (AZT) available under the
RETROVIR trade-mark from Glaxo-Wellcome Inc., Research Triangle, NC 27709;
didanosine (ddl) available under the VIDEX trade-mark from Bristol-Myers
Squibb Co.,
Princeton, NJ 08543; zalcitabine (ddC) available under the HIVID trade-mark
from
Roche Pharmaceuticals, Nutley, NJ 07110; stavudine (d4T) available under the
ZERIT
trade-mark from Bristol-Myers Squibb Co., Princeton, NJ 08543; lamivudine
(3TC)
available under the EPIVIR trade-mark from Glaxo-Wellcome, Research Triangle,
NC
l0 27709; abacavir (1592U89) disclosed in WO 96/30025 and available under the
ZIAGEN
trade-mark from Glaxo-Wellcome, Research Triangle, NC 27709; adefovir
dipivoxil
[bis(POM)-PMEA] available under the PREVON trade-mark from Gilead Sciences,
Foster City, CA 94404; lobucavir (BMS-180194), a nucleoside reverse
transcriptase
inhibitor disclosed in EP-0358154 and EP-0736533 and under development by
Bristol-
Myers Squibb, Princeton, NJ 08543; BCH-10652, a reverse transcriptase
inhibitor (in the
form of a racemic mixture of BCH-10618 and BCH-10619) under development by
Biochem Pharma, Laval, Quebec H7V 4A7, Canada; emitricitabine [(-)-FTC]
licensed
from Emory University under Emory Univ. U. S. Patent No. 5,814,639 and under
development by Triangle Pharmaceuticals, Durham, NC 27707; beta-L-FD4 (also
called
z o beta-L-D4C and named beta-L-2',3'-dicleoxy-5-fluoro-cytidene) licensed by
Yale
University to Vion Pharmaceuticals, New Haven, CT 06511; DAPD, the purine
nucleoside, (-)-beta-D-2,6,-diamino-purine dioxolane disclosed in EP 0656778
and
licensed by Emory University and the University of Georgia to Triangle
Pharmaceuticals, Durham, NC 27707; and lodenosine (FddA), 9-(2,3-dideoxy-2-
fluoro-
b-D-threo-pentofuranosyl)adenine, an acid stable purine-based reverse
transcriptase
inhibitor discovered by the NIH and under development by U.S. Bioscience Inc.,
West
Conshohoken, PA 19428.
The term "non-nucleoside reverse transcriptase inhibitors" ("NNRTI"s) as used
herein means non-nucleosides that inhibit the activity of HIV-1 reverse
transcriptase.
3 o Typical suitable NNRTIs include nevirapine (BI-RG-587) available under the
VIRAMUNE trade-mark from Boehringer Ingelheim, the manufacturer for Roxane
Laboratories, Columbus, OH 43216; delaviradine (BHAP, U-90152)
available under the RESCRIPTOR trade-mark from Pharmacia & Upjohn Co.,
CA 02371587 2005-05-05
-12-
Bridgewater NJ 08807; efavirenz (DMP-266) a benzoxazin-2-one disclosed in
WO 94/03440 and available under the SUSTIVA trade-mark from DuPont
Pharmaceutical Co., Wilmington, DE 19880-0723; PNU-142721, a furopyridine-thio-
pyrimide under development by Pharmacia and Upjohn, Bridgewater NJ 08807; AG-
1549 (formerly Shionogi # S-1153); 5-(3,5-dichlorophenyl)-thio-4-isopropyl-1-
(4-
pyridyl)methyl-1H-imidazol-2-ylmethyl carbonate disclosed in WO 96/10019 and
under
clinical development by Agouron Pharmaceuticals, Inc., LaJolla, CA 92037-1020;
MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4-(1H,3H)-
pyrimidinedione) discovered by Mitsubishi Chemical Co. and under development
by
to Triangle Pharmaceuticals, Durham, NC 27707; and (+)-calanolide A (NSC-
675451) and
B, coumarin derivatives disclosed in NIH U. S. Patent No. 5,489,697, licensed
to Med
Chem Research, which is co-developing (+) calanolide A with Vita-Invest as an
orally
administrable product.
The term "protease inhibitor" ("PI") as used herein means inhibitors of the
HIV-1
protease, an enzyme required for the proteolytic cleavage of viral polyprotein
precursors
(e.g., viral GAG and GAG Pol polyproteins), into the individual functional
proteins
found in infectious HIV-1. HIV protease inhibitors include compounds having a
peptidomimetic structure, high molecular weight (7600 daltons) and substantial
peptide
character, e.g. CRIXIVAN (trade-mark, available from Merck) as well as
nonpeptide
z o protease inhibitors, e.g., VIRACEPT (trade-mark, available from Agouron).
Typical suitable PIs include saquinavir (Ro 31-8959) available in hard gel
capsules under the INVIRASE trade-mark and as soft gel capsules under the
FORTOVASE trade-mark from Roche Pharmaceuticals, Nutley, NJ 07110-1199;
ritonavir (ABT-538) available under the NORVIR trade-mark from Abbott
Laboratories,
Abbott Park, IL 60064; indinavir (MK-639) available under the CRIXIVAN trade-
mark
from Merck & Co., Inc., West Point, PA 19486-0004; nelfnavir (AG-1343)
available
under the VIRACEPT trade-mark from Agouron Pharmaceuticals, Inc., LaJolla, CA
92037-1020; amprenavir (141 W94), trade-mark AGENERASE, a non-peptide protease
inhibitor under development by Vertex Pharmaceuticals, Inc., Cambridge, MA
02139-
4211 and available from Glaxo-Wellcome, Research Triangle, NC under an
expanded
access program; lasinavir (BMS-234475) available from Bristol-Myers Squibb,
Princeton, NJ 08543 (originally discovered by Novartis, Basel, Switzerland
(CGP-
CA 02371587 2005-05-05
-13-
61755); DMP-450, a cyclic urea discovered by Dupont and under development by
Triangle Pharmaceuticals; BMS-2322623 (atazanavir), an azapeptide under
development
by Bristol-Myers Squibb, Princeton, NJ 08543, as a 2nd-generation HIV-1 PI;
ABT-378
under development by Abbott, Abbott Park, IL 60064; and AG-1549 an orally
active
imidazole carbamate discovered by Shionogi (Shionogi #S-1153) and under
development by Agouron Pharmaceuticals, Inc., LaJolla CA 92037-1020.
Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12,
pentafuside
and Yissum Project No.l 1607. Hydroyurea (Droxia, trade-mark), a
ribonucleoside
triphosphate reductase inhibitor, the enzyme involved in the activation of T-
cells, was
to discovered at the NCI and is under development by Bristol-Myers Squibb; in
preclinical
studies, it was shown to have a synergistic effect on the activity of
didanosine and has
been studied with stavudine. IL-2 is disclosed in Ajinomoto EP-0142268, Takeda
EP-
0176299, and Chiron U. S. Patent Nos. RE 33,653, 4,530,787, 4,569,790,
4,604,377,
4,748,234, 4,752,585, and 4,949,314, and is available under the PROLEUKIN
i5 (aldesleukin) trade-mark from Chiron Corp., Emeryville, CA 94608-2997 as a
lyophilized powder for IV infusion or sc administration upon reconstitution
and dilution
with water; a dose of about 1 to about 20 million IU/day, sc is preferred; a
dose of about
million ILJ/day, sc is more preferred. IL-12 is disclosed in WO 96/25171 and
is
available from Roche Pharmaceuticals, Nutley, NJ 07110-1199 and American Home
z o Products, Madison, NJ 07940; a dose of about 0.5 microgram/kg/day to about
10
microgram/kg/day, sc is preferred. Pentafuside (DP-178, T-20) a 36-amino acid
synthetic peptide, disclosed in U .S. Patent No. 5,464,933 licensed from Duke
University
to Trimeris which is developing pentafuside in collaboration with Duke
University;
pentafuside acts by inhibiting fusion of HIV-1 to target membranes.
Pentafuside (3-100
as mg/day) is given as a continuous sc infusion or injection together with
efavirenz and 2
PI's to HIV-1 positive patients refractory to a triple combination therapy;
use of 100
mg/day is preferred. Yissum Project No. 11607, a synthetic protein based on
the HIV-1
Vif protein, is under preclinical development by Yissum Research Development
Co.,
Jerusalem 91042, Israel. Ribavirin, 1-/3-D-ribofuranosyl-1H-1,2,4-triazole-3-
3 o carboxamide, is available from ICN Pharmaceuticals, Inc., Costa Mesa, CA;
its
manufacture and formulation are described in U. S. Patent No. 4,211,771.
The term "anti-HIV-1 therapy" as used herein means any anti-HIV-1 drug found
useful for treating HIV-1 infections in man alone, or as part of
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-14-
multidrug combination therapies, especially the HAART triple and
quadruple combination therapies. Typical suitable known anti-HIV-1
therapies include, but are not limited to multidrug combination therapies
such as (i) at least three anti-HIV-1 drugs selected from two NRTIs, one PI,
a second PI, and one NNRTI; and (ii) at least two anti-HIV-1 drugs selected
from NNRTIs and Pls. Typical suitable HAART - multidrug combination
therapies include:
(a) triple combination therapies such as two NRTIs and one PI ; or
(b) two NRTIs and one NNRTI ; and (c) quadruple combination therapies
such as two NRTIs , one PI and a second PI or one NNRTI. In treatment of
naive patients, it is preferred to start anti-HIV-1 treatment with the triple
combination therapy; the use of two NRTIs and one PI is prefered unless
there is intolerance to Pls. Drug compliance is essential. The CD4+ and
HIV-1-RNA plasma levels should be monitored every 3-6 months. Should
viral load plateau, a fourth drug,e.g., one PI or one NNRTI could be added.
See the table below wherein typical therapies are further described:
ANTI-HIV-1 MULTI DRUG COMBINATION THERAPIES
A. Triale Combination Therapies
1. Two NRTIs' + one P12
2. Two NRTIs' + one NNRTI3
B. Quadruple Combination Therapies4
Two NRTIs + one PI + a second PI or one NNRTI
C. ALTERNATIVES:S
Two NRTI'
One NRT15 + one P12
Two Plss ~ one NRTI7 or NNRT13
One P12 + one NRTI' + one NNRTI3
FOOTNOTES TO TABLE
1. One of the following: zidovudine + lamivudine; zidovudine +
didanosine; stavudine + lamivudine; stavudine + didanosine;
zidovudine + zalcitabine
2. Indinavir, nelfinavir, ritonavir or saquinavir soft gel capsules.
3. Nevirapine or delavirdine.
4. See A-M. Vandamne et al Antiviral Chemistry & Chemotherapy
9:187 at p 193-197 and Figures 1 + 2.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-15-
5. Alternative regimens are for patients unable to take a recommended
regimen because of compliance problems or toxicity, and for those
who fail or relapse on a recommended regimen. Double nucleoside
combinations may lead to HIV-resistance and clinical failure in many
patients.
6. Most data obtained with saquinavir and ritonavir (each 400 mg
bid).
7. Zidovudine, stavudine or didanosine.
Agents known in the treatment of rheumatoid arthritis, transplant and
graft v. host disease, inflammatory bowel disease and multiple sclerosis
which can be administered in combination with the CCR5 antagonists of
the present invention are as follows:
solid organ transplant rejection and graft v. host disease: immune
suppressants such as cyclosporine and Interleukin-10 (IL-10), tacrolimus,
antilymphocyte globulin, OKT-3 antibody, and steroids;
inflammatory bowel disease: IL-10 (see US 5,368,854), steroids and
azulfidine;
rheumatoid arthritis: methotrexate, azathioprine, cyclophosphamide,
steroids and mycophenolate mofetil;
multiple sclerosis: interferon-beta, interferon-alpha, and steroids.
Certain CCR5 antagonist compounds of the invention may exist in
different isomeric (e.g., enantiomers, diastereoisomers and atropisomers)
forms. The invention contemplates all such isomers both in pure form and
in admixture, including racemic mixtures.
Certain compounds will be acidic in nature, e.g. those compounds
which possess a carboxyl or phenolic hydroxyl group. These compounds
may form pharmaceutically acceptable salts. Examples of such salts may
include sodium, potassium, calcium, aluminum, gold and silver salts. Also
contemplated are salts formed with pharmaceutically acceptable amines
such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine
and the like.
Certain basic compounds also form pharmaceutically acceptable
salts, e.g., acid addition salts. For example, the pyrido-nitrogen atoms may
form salts with strong acid, while compounds having basic substituents
such as amino groups also form salts with weaker acids. Examples of
suitable acids for salt formation are hydrochloric, sulfuric, phosphoric,
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-16-
acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic,
ascorbic,
malefic, methanesulfonic and other mineral and carboxylic acids well known
to those in the art. The salts are prepared by contacting the free base form
with a sufficient amount of the desired acid to produce a salt in the
conventional manner. The free base forms may be regenerated by treating
the salt with a suitable dilute aqueous base solution such as dilute aqueous
NaOH, potassium carbonate, ammonia and sodium bicarbonate. The free
base forms differ from their respective salt forms somewhat in certain
physical properties, such as solubility in polar solvents, but the acid and
base salts are otherwise equivalent to their respective free base forms for
purposes of the invention.
All such acid and base salts are intended to be pharmaceutically
acceptable salts within the scope of the invention and all acid and base
salts are considered equivalent to the free forms of the corresponding
compounds for purposes of the invention.
Compounds of the invention can be made by the procedures known
in the art, for example by the procedures described in the following reaction
schemes, by the methods described in the examples below, and by using
the methods described in US patents 5,883,096; 6,037,352; 5,889,006;
5,952,349; and 5,977,138.
The following solvents and reagents may be referred to herein by
the abbreviations indicated: tetrahydrofuran (THF); ethanol (EtOH);
methanol (MeOH); acetic acid (HOAc or AcOH); ethyl acetate (EtOAc);
N,N-dimethylformamide (DMF); trifluoroacetic acid (TFA); trifluoroacetic
anhydride (TFAA); 1-hydroxy-benzotriazole (HOBT); m-chloroperbenzoic
acid (MCPBA); triethylamine (Et3N); diethyl ether (Et20); tert-butoxy-
carbonyl (BOC); 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU); dimethyl-
sulfoxide (DMSO); p-toluene sulfonic acid (p-TSA); potassium
bis(trimethylsilyl)-amide (KHMDA); 4-dimethylaminopryidine (DMAP);
N,N,N-diiospropylethylamine (Dipea); and 1-(3-dimethyl-aminopropyl)-3-
ethyl carbodiimide hydrochloride (DEC). RT is room temperature.
Compounds of formula I and II .wherein X is CHO(C=O)-(C1-Cg)-
alkyl, CHO(C=O)-(C~-C6)alkoxy, CHO(C=O)-NH-(C1-C6)alkyl ,
CHNR5(C=O)-(C1-C6)alkyl, CHNRS(C=O)-(Ci-C6)alkoxy, CHNR5(C=O)-
NH-(Ci-Cg)alkyl or-CHOR3 (and wherein R~4, R~5 and R~6 are hydrogen)
are prepared according to Schemes 1-4:
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
_17_
Scheme 1
O O
R N R' standard R Ri 7
amidation N R ~ Z
1 ~N H ~ 2 ~N w
Z = CH, N p Rs
OH
Nab R ~N R' R~
MeOH ~ Z
~N w ~ 3
O R8
standard Raa\
esterification/ O 4a. R3a = alkyl etc
carbonation/ R R~ ~ 4b. R3a = COR3
carbamoylat!_on ~N R ~ sa s
4c. R = COOK
~N ~ 4d. R3a = CONHR3
O R8
or
~ R12
3 ~ ; 12 O Z
halogen ~Zi ~ R
R ~ R'
Z' = CH, N ~N R / Z
Base 5 ~N ~ I
i i
O R8
Compounds of formula 3, wherein R, R~ and R8 are as defined for
formula I, Z is CH or N, and R1 is an alkyl group such as methyl were
prepared as depicted in Scheme 1. Ketone 1, the synthesis of which was
described in W098/05292, was subjected to standard amidation with
ArCOOH, EDCI or DEC, and HOBT, or ArCOCI, wherein Ar is R~, R8-
substituted phenyl or pyridyl, followed by reduction with NaBH4 to obtain 3.
Derivatization of the free hydroxyl moiety with alkyl halides, acyl chlorides
(R3COC1), alkyl chloroformates (CICOOR3) and isocyanides (O=C=NR3)
afforded ethers 4a, esters 4b, carbonates 4c, and carbamates 4d,
respectively, wherein R3 is a lower alkyl group. The aryloxy compounds, 5,
were obtained after condensation of the hydroxyl 3 with phenyl or pyridyl
halides in the presence of a base.
Scheme 2
O OH
R N R~ N~ R
MeOH N R
1a ~NBoc
~N Boc
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-18-
,2
\!~R,2 ~ ~jR
' O Z
halo en
g Z
Base R ~~ R'
N
Or i
1'~ R 7 ~NBoc
OH Z
PPh3, R2°02C-N=N-C02R2°
~ R, 2
O ~Z~J
7 ~ ) TF~ R ,
2) standard N R R~
amidation ~ Z
~N w I
O R8
Alternatively, compounds of formula 5 can be prepared by reduction
of the N-Boc ketone 1 a to the alcohol 6 first, followed by functionalization
of
the free hydroxyl group with a halogen-substituted aryl in the presence of a
base as shown in Scheme 2, or by a hydroxy-substituted aryl or heteroaryl
(wherein Z~ is as defined in Scheme 1 ) in the presence of PPh3 and an
azodicarboxylate of the formula R~902C-N=N-C02R2o, wherein R2o is C~-
C6 lower alkyl. Removal of the Boc protecting group and conversion to the
amide is performed as in Scheme 1. This route allows the introduction of
various aryloxy and heteroaryloxy moieties at R3 through the use of
nucleophilic displacement or Mitsunobu-type reaction on intermediate 6.
Scheme 3
NH2
1 ) CH30NH2. HCI R i
2) BH3.SMe2 N R R7 i Z
8 ~N w I
CICOOR2° p R8
O O=C=N
R 3
HN OR HN~NHR3
R ~N R1 R7
i Z R N R1 R~
~N w
I 10 ~N W
O Rs O R8
15 Compounds of formula 8, wherein R, R~ , R~, R8 and Z are as
described in Scheme 1, were prepared by conversion of the ketone 2 to an
oxime group with CH30NH2~HC1, and reduction with BH3~S(CH3)2 to
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
_19_
provide amine 8. Derivatization of the free amine moiety with an alkyl
chloroformate (CICOOR2~, wherein R2~ is C1-C6 alkyl) or an isocyanide
(O=C=NR3) affords carbamate compounds 9 and urea compounds 10,
respectively.
Scheme 4
Boc=AA-OH Boc-AA-O Boc-AA-O
EDC~ R N R1 + R~~N R~
11a ~NBoc 11b ~NBoc
, Ri2
O Z
i
11a 1) Nay R ~N R R~ i Z
or
11 b 2) , 12a ~N w i
Riz or
halogen ~Z~J i , ~2 O R
Base _ ~ ~ ~ R
O Z
3) TFA
4) standard R R'
amidation /~N R i Z
12b ~N
O R$
Preparation of chiral analogs was performed through chemical
resolution. The alcohol 6 was coupled with a chiral Boc-protected amino
acid to obtain diastereoisomers 11 a and 11 b which were separated by
chromatography. The chiral auxialiary was then removed with NaOH for
each diastereoisomer and the same sequence of reactions described in
Scheme 2 was carried out on each individual enantiomer to obtain
compounds 12a and 12b.
Oximes of formula I or II wherein X is C=NOR4 are prepared from
the corresponding ketones from any of several methods known to those
skilled in the art.
Scheme 5:
O ~~OR4
R~N R~ NH20R4~HCI, NaOAc R R'
~N
1a ~N~BOC ~N~
13 BOC
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-20-
N",.~OR4
1 ) TFA
R
EDCI ~N R
R C02H HOBT ~N Rz
DIPEA if
O
In Scheme 5, the ketone 1a, wherein R and Ri are as defined for
formula I and II, is dissolved in a solvent such as CH30H or ethanol and
treated with an R4-substituted hydroxylamine such as O-methylhydroxyl-
amine hydrochloride in the presence of a base such as sodium acetate.
The resulting mixture of Z- and E-O-substituted oximes 13 can be
separated or the mixture carried through and separated at the end. The
BOC protecting group is removed by treatment with an acid such as
aqueous HCI or trifluoroacetic acid, and the resulting amine is coupled to
an acid under standard conditions to obtain a compound of formula I or II.
Scheme 6:
..OR4
NH20H~HCI, N~OH ~ Base
~N R _
NaOAc R ~ ) R~ R1
2) alkylating N
14 ~N~ agent ~ 5 ~N-BOC
BOC
fOR4
~ ) TFA
2) R2C0 H EDCI R~N R'
HOBT
DIPEA ~N~R2
O
Alternatively, the ketone 1 a can be treated with HONH2~HC1 under
similar conditions to yield, after separation, the E- and Z-oximes. Each
15 oxime is then treated with a base such as potassium hexamethyldisilazide
in a suitable solvent such as DMF followed by treatment with an alkylating
agent, e.g., CH31, dimethylsulfate, CH3CH21, trifluoroethyl triflate or
similar
electrophiles, to yield the desired O-substituted oxime.
The ketone starting material of formula 1a can be prepared by
known methods as shown in Schemes 7 and 8.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-21 -
Scheme 7:
C02H COCI O (CH20H)2 p O
1. TFAA ~ ~. AIC13, R-H p-TSA
R ~ R
2. SOCI ~NCOCF3 Toluene %~NCOCF3
2 N
16 COCF3 1$ 19
CH OH, 17 !~ Ti(OPr)4 O~1
H20, O O O R O N
19 K2C03 R Et AICN %~N
/~N H 2
N
20 N 21
BOC ~BOC
O~
O 1 ) HCI
21 R~MgBr R~'~ R~ ~ 1a
N 2) BOC20
22 ~N-gOC
In Scheme 7, Friedel-Crafts condensation of N-trifluoroacetyl-
isonipecotoyl chloride 17 and an aromatic group R-H in the presence of a
suitable catalyst such as AIC13 and optionally in a solvent such as CH2C12
yields a ketone 18 which is converted to its ethylene ketal 19 under
standard conditions. The N-trifluoroacetyl group is removed and the
resulting free amine 20 is treated with N-BOC-piperidine-4-one in the
presence of a dehydrating agent such as titanium isopropoxide followed by
treatment with diethylaluminum cyanide to give an aminonitrile 21. The
aminonitrile is treated with a grignard reagent (R1 Mg-halide) such as
CHgMgBr or vinylmagnesium bromide to give the alkylated product 22. The
ketal is removed by treatment with aqueous acid followed by re-protection
under standard conditions using BOC anhydride to give 1a.
Scheme 8:
O 1. HCI, 2. DBU, Ti(OPr)4
Ph3P=CH2 RAM Br
--~ O NCN ~ NR~
BOC BOC ~ Et2AICN
23 N N N
BOC BOC 24 25 BOC
HO H O R OH
BH3~THF Desosr Martin R-Li Dess-Martin
' N ~ TPAP ~ ~ 1 a
~R N R~ THF, -78°C N Ri or
TPAP/NMO
26 BOC 27 gOC 28 BOC
Alternatively, 23, prepared via Wittig olefination of N-BOC-piperidone
20 (Chen et al, Tetrahedron Lett., 37, 30 (1996), 5233-5234), is transformed
to
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-22-
intermediate 25 by analogy to the procedure described in Scheme 7. 25 is
converted to alcohol 26 by hydroboration/oxidation. Alcohol 26 is treated
with a suitable oxidant such as a mixture tetrapropylammonium
perruthenate (TPAP) and N-methylmorpholine N-oxide (NMO) to give
aldehyde 27. The aldehyde is treated with an aryllithium reagent in a
suitable solvent such as ether or THF and the resulting alcohol 28 is
treated with an oxidizing agent such as Dess-Martin periodinane or
TPAP/NMO to give the desired ketone.
Compounds of formula I or II wherein X is -C(R~3)(R~9)-, wherein R
and R~9 are the same, or wherein R and R~9 are different are prepared
according to schemes 9 and 10, respectively. The schemes are
exemplified by processes wherein R and R19 are each phenyl and wherein
R is phenyl and R~9 is CF3-phenyl, respectively, but the general
procedures apply to other R and R~9 groups.
Scheme 9
gr PhB(OH)2
O CBr4 PdCl2(PPh3)2 ~ I ~ 45
Br
~N~Boc
PPh3 N-goc THF/H20
CH3CN 44 Na2C03 I ~ N'Boc
H2
Pd(OH)2
i
i ~ i
TFA
I i ~N ~ w ~ I w
~N R2 i N. i N.
48 ~ 4~ H 46 goc
O
N-BOC-4-piperidone is treated with CBr4 to obtain the di-bromo
compound of formula 44, which is then treated with phenylboronic acid to
obtain the BOC-protected diphenylmethylene-piperidine of formula 45. The
methylene bond is reduced using standard conditions to obtain the BOC-
protected diphenylmethyl-piperidine of formula 46, the BOC group is
removed and the amine of formula 47 is treated as described for
compounds 20-22 of Scheme 7, the BOC group is removed by treatment
with TFA, and the resultant amine subjected to a standard amidation
procedure, e.g., treatment with a reagent R2COOH and coupling agents
such as EDCI, HOBT and a base, to obtain the compounds of formula 48.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-23-
Scheme 10
H Br
\ ~ 1)Br2 \ \
NaH ' I ~ N~Q"~ _ ( ~ N~Q""
phosphonate 49 50
,~ TFA
Br
1 ) Ti(OiPr)4 Br
N CN N-BOC-4-Piperidone \ \
I i N.
52 ~N~BOC 2) Et2AICN H
51
1CH3MgBr CF3
Br 4_CF3C6H4g(OH)2 I i
\ \ Pd(PPh~)d
I / N \ ~
~N, THF/H20 I i N
53 BOC Na2C03 54 ~N-
BOC
H2
1 Pd(OH)2
C\ a CFs
I \
/ I/
\ t- s
/ N~ I / N
2
+ 56 N R + 55 ~N
- 0 - BOC
N-BOC-4-piperidone is treated with a reagent such as diethyl
benzylphosphonate to obtain the phenylmethylene-piperidine of formula 49,
which is then brominated to obtain the bromophenylmethylene-piperidine of
fomula 50. The BOC protecting group is removed using standard
conditions, e.g., treatment with TFA, to obtain amine 51, and the amine 51
is treated as described for compounds 20-22 of Scheme 7 to obtain the
aminonitrile 52, then the protected amine 53. The amine 53 is treated with
a reagent such as 4-CF3-phenylboronic acid to obtain compound 54 and
the methylene bond is reduced using standard conditions to obtain racemic
55. The BOC group is removed by treatment with TFA, and the resultant
amine subjected to a standard amidation procedure, e.g., treatment with a
reagent R2COOH and coupling agents such as EDCI, HOBT and a base, to
obtain the racemic compounds of formula 56.
Compounds useful in this invention are exemplified by the following
preparative examples, which should not be construed to limit the scope of
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-24-
the disclosure. Alternative mechanistic pathways and analogous structures
within the scope of the invention may be apparent to those skilled in the art.
Example 1
O COCI O
H3C ~ CH3
CH3 w I ~ CH3 H3C
Br ~ ~' N Bra N
29 ~NH NaOH/CH2C12 30 N
OH OR3 O CH3
NaBH
H C
CH30H Br w ~ N CH3H3C / Br ~ I N CH3
31 N ~ I N ~
O CH3 1 A. R3 = -CH2CH3 O CH3
1 B. R3 = -COCH2CH3
1 C. R3 = -COOCH3
1 D. R3 = -CON-ICH3
1 E. R3 = ~ ~ \
A solution of free amine 29 (1.45 g, 3.97 mmol) and 2,6-dimethyl-
benzoyl chloride (840 mg, 5.0 mmol) in aqueous 1 N NaOH (20 ml) and
CH2C12 (20 ml) was stirred overnight at RT. The reaction mixture was
extracted with CH2C12, dried over Na2S04 and concentrated under high
vacuum to provide 30 (1.97 g, 97%), as a slightly yellow foam.
To a solution of ketone 30 (550 mg, 1.11 mmol) in CH30H (6 ml)
was added NaBH4 (60 mg, 1.59 mmol) and the solution was stirred
overnight at RT. The reaction mixture was then poured into 0.1 N NaOH,
extracted with CH2C12, dried over Na2S04, and concentrated to give 31
(543 mg, 98%), as a slightly yellow foam.
Example 1 A:
To a solution of alcohol 31 (50 mg, 0.10 mmol) in anhydrous DMF
(0.5 ml) was added NaH (6.0 mg, 0.25 mmol) followed by ethyl iodide (12
,ul, 0.15 mmol) and the reaction was stirred 4 h at 40 °C. The reaction
mixture was poured into aqueous 0.1 N NaOH, extracted with CH2C12,
dried over Na2S04, and concentrated. Purification by preparative
chromatography (eluting with CH2C12/CH30H, 9:1 ) yielded 1 A (31 mg,
59%) as a colorless oil: ~ H -NMR (300 MHz, CDCIg) 8 7.39 (br d, J = 8.4
Hz, 2H), 7.02-7.12 (m, 3H), 6.95 (m, 2H), 3.94 (m, 1 H), 3.79 (d, J = 7.2 Hz,
1 H), 3.10-3.35 (m, 4H), 2.60-3.00 (m, 3H), 2.19 (br s, 6H), 1.60-2.10 (m,
5H), 1.05-1.50 (m, 5H), 1.08 (br t, 3H), 0.94 (s, 3H); HRMS (MH+)
527.2271.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-25-
Example 1 B:
To a solution of alcohol 31 (50 mg. 0.10 mmol) and pyridine (16.2 ~I,
0.20 mmol) in anhydrous CH2C12 (0.5 mL) was added propionyl chloride
(30 NI, 0.30 mmol) and the solution was stirred overnight at RT. The
reaction mixture was treated as for 1 A to give, after preparative
chromatography (eluting with CH2C12/CH30H, 9:1 ), 1 B (44.7 mg, 81 %) as
a colorless oil: ~ H -NMR (300 MHz, CDC13) 8 7.42 (br d, J = 8.2 Hz, 2H),
7.05-7.15 (m, 3H), 6.97 (m, 2H), 5.40 (d, J = 7.8 Hz, 1 H), 4.09 (m, 1 H),
3.43 (m, 1 H), 3.23 (m, 1 H), 2.96 (m, 1 H), 2.82 (m, 1 H), 2.70 (m, 1 H),
2.21
(d, 3H), 1.60-2.10 (m, 5H), 1.05-1.45 (m, 5H), 1.08 (m, 3H), 0.95 (s, 3H);
HRMS (MH+) 555.2230.
Example 1 C: To a solution of alcohol 31 (29.4 mg, 0.059 mmol) and
pyridine (9.5,u1, 0.118 mmol) in anhydrous CH2C12 (0.3 mL) was added
methylchloro-formate (13.8,u1, 0.18 mmol) and the solution was stirred
overnight at RT. The reaction mixture was treated as for 1A to give, after
preparative chromatography (eluting with CH2C12/CH30H, 9:1 ), 1 C (15 mg,
46%) as a colorless oil: 1 H -NMR (300 MHz, CDC13) 8 7.46 (br d, J = 8.4
Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.09 (m, 1 H), 6.98 (m, 2H), 5.21 (d, J =
7.2 Hz, 1 H), 4.09 (m, 1 H), 3.71 (m, 3H), 3.45 (m, 1 H), 3.24 (m, 1 H), 2.97
(m, 1 H), 2.82 (m, 1 H), 2.70 (m, 1 H), 2.22 (br s, 3H), 1.60-2.10 (m, 5H),
1.10-1.50
(m, 5H), 0.95 (s, 3H); HRMS (MH+) 557.2017.
Example 1 D:
A solution of alcohol 31 (30 mg, 0.060 mmol), pyridine (9.7,u1, 0.12
mmol) and methylisocyanate (40 NI, 0.68 mmol) in anhydrous THF (0.3 ml)
was stirred 5 h at 45 °C. The reaction mixture was treated as for 1A to
give, after preparative chromatography (eluting with CH2C12/CH30H, 9:1 ),
1 D (25 mg, 75%) as a colorless oil: 1 H -NMR (300 MHz, CDC13) 8 7.42 (br
d, J = 8.2 Hz, 2H), 7.05-7.15 (m, 3H), 6.98 (m, 2H), 5.34 (m, 1 H), 4.08 (m,
1 H), 3.44 (m, 1 H), 3.24 (m, 1 H), 3.19 (s, 3H), 2.96 (m, 1 H), 2.65-2.85 (m,
2H), 2.20 (br s, 3H), 1.55-2.10 (m, 5H), 1.10-1.50 (m, 5H), 0.95 (s, 3H);
HRMS (MH+) 556.2169.
Example 1 E:
A solution of alcohol 31 (50 mg, 0.10 mmol), NaH 60% in mineral oil
(6 mg, 0.15 mmol), and 2-chloropyridine (28.2,u1, 0.30 mmol) in anhydrous
DMF (0.5 ml) was stirred 16 h at 90 °C. The reaction mixture was
treated
as for 1 A to give, after preparative chromatography (eluting with
CH2C12/CH30H, 9:1 ), 1 E (50 mg, 86%) as a colorless oil: 1 H -NMR (300
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-26-
MHz, CDC13) 8 7.98 (m, 1 H), 7.47 (br t, J = 7.2 Hz, 1 H), 7.38 (d, J = 8.0
Hz,
2H), 7.21 (d, J = 8.0 Hz, 2H), 6.95-7.15 (m, 3H), 6.65-6.80 (m, 2H), 5.74 (br
d, J = 7.0 Hz, 1 H), 4.09 (m, 1 H), 3.44 (m, 1 H), 3.24 (m, 1 H), 2.65-3.05
(m,
3H), 2.22 and 2.23 (s, 3H), 1.60-2.15 (m, 5H), 1.10-1.50 (m, 5H), 0.87 (s,
3H); HRMS (MH+) 576.2230.
Using similar procedures, compounds of the following structure were
prepared
.R3
O
CH3
Rs ~ I N
~N R2
O
wherein R3. R6 and R2 are as defined in the table:
Ex. R6 R3 R2 HRMS
MH+ found
1 Br -C(O)OCH2CH3 H3C ~ CH3 571.2181
F I~
1 Br -C(O)CH3 H3C ~ CH3 541.2054
G I
1 Br -C(O)-(CH2)2CH3 ~ 569.2392
H H3C I ~ CH3
11 Br -C(O)NHCH2CH3 H3C ~ CH3 572.2322
I~
1 Br S~ H3C ~ CH3 584.1786
J ~N I
1 Br ~~ H3C ~ CH3 577.2162
K I
N ~ 577.2183
1 Br ~~~ H3C I \ CH3
L
Additional data for comaounds of Examale 1:
Ex. 1H-NMR (300 MHz'H NMR (CDC13))
1 7.49 (d, J = 8.4 Hz, 2H), 7.20-7.35 (m, 3H), 7.15
J (m, 1 H), 7.04 (m,
2H), 6.64 (d, J = 4.5 Hz, 1 H), 5.58 and 5.60 (d,
J = 7.2 Hz, 1 H), 4.13
(m, 1 H), 3.25-3.60 (m, 2H), 2.70-3.10 (m, 3H), 2.28
and 2.29 (s, 3H),
1.65-2.20 m, 5H , 1.20-1.55 m, 5H , 0.92 br s, 3H
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-27-
1 K 8.39 (d, J = 5.6 Hz, 1 H), 7.42 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 8.4 Hz,
2H), 7.05-7.20 (m, 2H), 6.99 (m, 2H), 6.84 (m, 1 H), 5.70 (d, J =
7.8Hz, 1 H), 4.11 (m, 1 H), 3.43 (m, 1 H), 3.25 (m, 1 H), 2.65-3.05 (m,
3H), 2.23 and 2.25 (s, 3H), 1.55-2.10 (m, 5H), 1.10-1.50(m, 5H), 0.88
br s, 3
Example 2
O OH
NaBH4
CH3 ---~ \ I CH3
CH3S02 \ N CH30H CH3S02 N
32 NBoc ~ 33 NBoc
O"N.
~I
Br~ i I CH3
33 KHMD CH SO \ I ~N
3 2 I
34a. R2a- Boc N ~ R2a
34b. R2a - H ~ TFA
O ~N
COOH
H3C~CH3 ~ ~~ CHg
34b -.~ CHgSO2 \ ~ N H3C ~ I
EDCI/HOBt 35 N \ N
O CHs
A solution of ketone 32 (0.60 g, 1.29 mmol) and NaBH4 (60 mg, 1.59
mmol) in CH30H (5 ml) was stirred overnight at RT. The reaction mixture
was poured into 0.1 N NaOH, extracted with CH2C12, dried over Na2S04,
and concentrated to give 33 (0.60 g, 100%), as a white foam.
To a solution of alcohol 33 (543 mg, 1.2 mmol) in anhydrous toluene
(4 ml) was added KHMDA, 0.5 N in toluene (2.6 ml, 1.30 mmol) followed,
15 min. later, by 2-bromopyridine (125,u1, 1.30 mmol). The reaction was
heated 5 h at 60 °C, cooled to RT and poured into 5% aqueous NaHC03
(25 ml). Extraction with CH2C12, drying over Na2S04 and concentration
afforded an oil which was purified by flash chromatography over silica gel
(eluting with CH2C12/AcOEt/Et3N 50:50:1 to 40:60:1 ) to yield 34a (310 mg,
49%), as a yellow foam.
A solution of 34a (310 mg, 0.57 mmol) in anhydrous CH2C12 (2 ml)
and TFA (2 ml) was stirred 30 min. at RT. After concentration, the residue
was taken up in aqueous 1 N NaOH, extracted with CH2C12, dried over
Na2S04 and concentrated to give 34b (220 mg, 87%), as a white foam.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-28-
A solution of free amine 34b (85 mg, 0.19 mmol), 2,4-dimethyl-
nicotinic acid (50 mg, 1.45 mmol), DEC (60 mg, 0.31 mmol), HOBT (50 mg,
0.37 mmol) and N-methylmorpholine (80 ml, 0.72 mmol) in anhydrous DMF
(1 ml) was stirred overnight at 40 °C. After concentration, the residue
was
taken up in aqueous 0.1 N NaOH, extracted with CH2C12, and dried over
Na2S04. The residue obtained after concentration of the solvent was
purified by preparative chromatography over silica gel (eluting with
CH2C12/CH30H/NH40H, 96:4:1 ) to afford 35 (95 mg, 85%), as a colorless
oil: ~ H -NMR (300 MHz, CDC13) 8 8.33 (d, J = 5.1 Hz, 1 H), 7.99 (dd, J = 4.8
and 1.8 Hz, 1 H), 7.86 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 7.53 (m,
1 H), 6.96 (d, J = 5.1 Hz, 1 H), 6.75-6.85 (m, 2H), 4.15 (m, 1 H), 3.45 (m, 1
H),
3.30 (m, 1 H), 3.02 (s, 3H), 2.99 (m, 2H), 2.79 (m, 1 H), 2.47 and 2.48 (s,
3H), 2.45 (m, 1 H), 2.25 and 2.26 (s, 3H), 1.65-2.15 (m, 5H), 1.15-1.55 (m,
5H), 0.90 (s, 3H); HRMS (MH+) 577.2858.
Using similar procedures, compounds of the following structure were
prepared
.R3
O
i I ~1 CHs
R6 w N
N~R2
O
wherein R3_ R6 and R2 are as defined in the table:
Ex. R6 R3 R2 HRMS (MH+)
found
2A Br N I CI ~ NH2 599.1062
i
2B Br ~ I H3C ~ OH 578.2006
'N ~ I w
i
2C Br N I H3C ~ CH3 577.2172
I
~N
2D Br ~ I ~ 577.2172
~N ~',, HsC ~ NH2
I~
2E H3CS02- N I CI ~ NH2 597.2296
I~
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-29-
2F HgCS02- ~ ~ H C ~ OH 578.2697
~N ~sr' s
i
2G F3C- ~ ~ ~ 567.2947
.N ~' H3C ~ CH3
I ,N
2H HgCS02- N ~ H3C ~ CH3 576.2890
i
21 H3CS02- I N H3C ~ CH3 593.2805
2J F3C0- I N H3C ~ CH3 582.2969
i
2K F3CG- ~ ~ ~ 584.2744
.~ N H3C ~ OH
i
2L F3CG- ~ ~ ~ 583.2913
N H3C I w CH3
~N
2M Br ~N~ ~ 580.2123
NJ H3C I ~ CH3
,N
2N gr ~ N'1
J 579.1986
H3C I ~ OH
20 F3C0- ( ~ ~ 599.2847
N H3C ~ CH3
I , N,
a0
2P Br I N H3C ~ CH3 595.2114
I ~~
2Q Br ~~~ ~ 594.2072
H3C I ~ CH3
N~~
2R H3CS02- ( ~ H C~CH 578.2792
N 3 I ~ 3
NvN
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-30-
2S H3CS02- rN,l H3C ~ CH3 578.2801
'~~:N J
~N
2T H3CS02- ~N~~ H3C ~ CH3 594.2750
~,~:N
. N
2U HgCS02- ~IN H C ~ CH3 583.2426
3
I ~N
2V H3CS02- \ I H C ~ CH 576.2896
3 I ~ 3
~N
2W HgCS02- ~IN H C ~ CH 599.2362
3 I w 3
Ny
2X FgC- ~ N H C ~ CH 583.2905
3 ( ~ 3
N~~
2Y F3C0- \ N H3C- CH 584.2848
s
NON
2Z FgCO- \ N CI ~ CI 623.1790
I ~~
N'
2AA CI ~ N H C ~ CH 533.2673
3 I ~ 3
~N
2BB CI ~ N ~ 549.2646
H3C ~ CH3
I i
N~~
2CC CI ~ N CI ~ CI 573.1606
N'
2DD CI ~ N H3C~CH 534.2637
f, y s
NON
2EE Br ~ N CI ~ CI 619.1062
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-31 -
2FF H3CS02- ~~ H3C~CH 584.2375
\ 3
NvN
2GG FsC- \ N H3C~CH 568.2913
I\ s
NON
2HH H3CS02- ~N CI ~ CI 618.1722
I
N'
211 H3CS02- ~N H3C~CH 579.2749
I \ 3
NON
2JJ FsC- \ N CI ~ CI 607.1871
N'
2KK F N ~ H3C ~ CH3 517.2696
I .N
2LL F N ~ H C ~ CH3 533.2916
3
. N~~
2MM F I ~ H C~CH 518.2944
N 3 I \ 3
NvN
2NN CI N ~ CI ~ CI 589.1534
'~ I NJ
200 F N ~ CI ~ CI 573.1818
I N
2PP Br H3C I w H3C ~ CH3 591.2330
N
I ~N
2Q0 gr H3C I ~ H C ~ CH 607.2291
3 I w 3
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-32-
2RR Br H3 I ~ H C~CH 592.2294
3 ~ ~ 3
NON
2SS Br I ~ CI ~ CI 633.1040
I~
C
2~ F3C- I ~ CI ~ CI 623.1809
I
N
2UU F3C- \ N CH3 ~ CH3 583.2909
i NJ
_~
2VV F3C- \ N CH3 ~ CH3 567.2961
I ~~
2WW F ~ N H C ~ CH 532.3106
3 ~ 3
NYN
CH3
2XX H ~ N H3C~CH 500.3023
,, i ~ s
NvN
Additional data for compounds of Example 2:
Ex. 1 H-NMR (300 MHz'H NMR (CDC13))
2A 7.98 (m, 1 H), 7.49 (br t, J = 7.1 Hz, 1 H), 7.39
(d, J = 8.1 Hz, 2H),
7.12 (d, J = 8.1 Hz, 2H), 7.01 (t, J = 8.4 Hz, 1
H), 6.65-6.80 (m, 3H),
6.56 (d, J = 8.4 Hz, 1 H), 5.76 (d, J = 7.2 Hz, 1
H), 3.95-4.20 (m, 1 H),
3.89 and 3.92 (s, 2H), 3.30-3.55 (m, 2H), 3.12 (m,
1 H), 2.70-3.00
m, 2H , 1.65-2.10 m, 5H , 1.20-1.60 m, 5H , 0.95
and 0.99 s, 3H
2G 8.31 (d, 1 H), 8.01 (d, 1 H), 7.50 (m, 4H), 6.95
(d, 1 H), 6.80 (m, 2H),
5.90 (d, 1 H), 4.15 (d, 1 H), 3.25-3.55 (m, 2H),
2.80-3.15 (m, 3H),
2.50 (d, 3H), 2.30 (d, 3H), 1.80-2.15 (m, 7H), 1.20-1.60
(m, 5H),
0.92 s, 3H
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-33-
I 7.97 (m, 1 H), 7.45 (m, 1 H), 7.32 (t, J = 8.4 Hz,
2K 2H), 7.06 (m, 2 H),
7.01 (m, 1 H), 6.60-6.75 (m, 4H), 5.77 and 5.79 (d,
J = 5.6 Hz, 1 H),
3.55 (m, 1 H), 3.32 (m, 1 H), 2.70-2.95 (m, 2H),
2.18 (s, 3H), 1.65-
2.10 m, 5H , 1.15-1.55 m, 5H , 0.78 and 0.91 s, 3H
2M 8.29 (d, J = 5.2 Hz, 1 H), 8.18 (m, 1 H), 7.98 (br
s, 1 H), 7.89 (br s,
1 H), 7.38 (d, J = 8.4 Hz, 2H), 7.18 (d, J = 8.4
Hz, 2H), 6.92 (d, J =
5.2 Hz, 1 H), 5.67 (d, J = 7.2 Hz, 1 H), 4.07 (m,
1 H), 3.43 (m, 1 H),
3.26 (m, 1 H), 2.65-3.05 (m, 3H), 2.41 and 2.42 (s,
3H), 2.20 (br s,
3H , 1.60-2.20 m, 5H , 1.05-1.50 m, 5H , 0.85 br
s, 3H
2P 8.14 (d, J = 6.8 Hz, 1 H), 8.02 (m, 1 H), 7.51 (m,
1 H), 7.41 (d, J = 8.0
Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H), 6.98 (d, J = 6.4
Hz, 1 H), 6.78 (m,
1 H), 6.73 (m, 1 H), 5.78 (d, J = 6.8 Hz, 1 H), 4.17
(m, 1 H), 3.43 (m,
1 H), 3.32 (m, 1 H), 2.95 (m, 1 H), 2.86 (m, 1 H),
2.75 (m, 1 H), 2.44
and 2.46 (s, 3H), 2.23 and 2.25 (s, 3H), 1.65-2.10
(m, 5H), 1.15-
1.50 m, 5H , 0.90 s, 3H
2HH 8.49 (s, 2H), 8.26 (br s, 1 H), 8.04 (br s, 1 H),
7.80-7.95 (m, 3H), 7.53
(d, J = 8.4 Hz, 2H), 5.81 (d, J = 6.8 Hz, 1 H), 4.16
(m, 1 H), 3.30-3.50
(m, 2H), 2.94 (m, 2H), 2.80 (m, 1 H), 1.75-2.15 (m,
5H), 1.25-1.50
m, 5H , 0.89 s, 3H
2MM 8.93 (s, 1 H), 8.04 (br d, J = 4.8 Hz, 1 H), 7.50
(m, 1 H), 7.32 (m, 2H),
6.97 (m, 2H), 6.78 (m, 1 H), 6.72 (m, 1 H), 5.82
(m, 1 H), 4.21 (m,
1 H), 3.25-3.50 (m, 2H), 2.93 (m, 2H), 2.78(m, 1
H), 2.44 and 2.46 (s,
3H), 1.90-2.15 (m, 3H), 1.70-1.90 (m, 2H), 1.15-1.50(m,
5H), 0.90(s,
3H
2NN 8.17 (s, 1 H), 8.01 (br d, J = 4.0 Hz, 1 H), 7.50
(br t, J = 8.0 Hz, 1 H),
7.20-7.35 (m, 4H), 6.78 (t, J = 6.8 Hz, 1 H), 6.71
(m, 1 H), 5.80 (d, J
= 6.8 Hz, 1 H), 4.18 (m, 1 H), 3.44 (m, 1 H), 3.39
(m, 1 H), 3.00 (m,
2H), 2.80 (m, 1 H), 1.70-2.15 (m, 5H), 1.10-1.50
(m, 5H), 0.90 (s,
3H
2PP 8.37 (d, J = 6.0 Hz, 1 H), 7.83 (br d, J = 4.6 Hz,
1 H), 7.41 (d, J = 8.4
Hz, 2H), 7.34 (d, J = 6.0 Hz, 1 H), 7.22 (d, J =
8.4 Hz, 2H), 6.97 (d,
J = 4.6 Hz, 1 H), 6.68 (br t, J = 6.0 Hz 1 H), 5.89
(br d, J = 6.8 Hz,
1 H), 4.20 (m, 1 H), 3.20-3.50 (m, 2H), 2.97 (m,
2H), 2.78 (m, 1 H),
2.47 and 2.49 (s, 3H), 2.23 and 2.26 (s, 3H), 2.23
(s, 3H), 1.65-2.15
m, 5H , 1.15-1.55 m, 5H , 0.90 s, 3H
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-34-
Example 3
H3C0-~ N
i
CH30NH2. HCI ~ ~ ~~ CHs
w N H3C
30 AcONa / EtOH Br N ~ ~ 36
O CH3
NH2
BH3~THF ~ I ~1 CH3
36 ~ N H3C ~
Br 37
N
O O CH3
CICOOCH3 HN~OCH3
37 i CH3
Br ~ I N H3C ~
N ~ ~ 38
O CH3
To a solution of ketone 30 (1.5 g, 3.22 mmol) in CHgOH (50 ml) was
added sodium acetate (5.0 g, 47 mmol) and O-Methyl hydroxylamine
hydrochloride (3.26 g, 47 mmol), and the solution was stirred at RT for
24 h. The resulting mixture was then poured into aqueous NaOH and
extracted with CH2C12. The combined extracts were dried, concentrated
and chromatographed to yield 1.50 g (94%) of oxime 36, as a mixture of E
and Z isomers.
To a stirred solution of oxime 36 (0.200 g, 0.380 mmol) in THF (5 ml)
was added BH3~THF (1.0 M solution in THF) at 0 °C and the solution was
then warmed to RT and stirred for 1 h. The reaction mixture was then
cooled to 0°C and a solution of 1 N KOH in CH30H (5 ml) was added. The
reaction was warmed slowly to 60°C for 2 h, cooled to RT, quenched with
water and extracted with CH2C12. Combined organic layers were
concentrated and chromatographed over silica gel (eluting with 20%
EtOH/EtOAc) to afford 0.100 g (50%) of amine 37.
To a stirred solution of amine 37 (0.015 g, 0.030 mmol) was added
pyridine (0.5 ml) and CICOOCHg (0.25 ml), and the solution was stirred
overnight. It was then poured into water, extracted with EtOAc, dried,
concentrated and purified by preparative chromatography to give 0.010 g of
desired product 38: ~ H-NMR (300 MHz, CDC13) 8 7.45 (d, 2H), 7.05-7.12
(m, 3H), 6.95 (d, 2H), 4.95 (m, 1 H), 4.45 (m, 1 H), 4.15 (m, 1 H), 3.62 (s,
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-35-
3H), 3.47 (m, 1 H), 3.25 (m, 1 H), 2.88-3.10 (m, 3H), 2.25 (s, 6H), 1.20-2.10
(m, 12H), 0.90 (s, 3H); HRMS (MH+) 558.3013.
Example 4
OH Boc-Thr(tBu)-O
Boc-Thr(iBu)-OH
N CH3 EDCI, DMAP \ ~ N CHs
Br Br
~N Boc
39ab 40a ~NBoc
First eluted
Boc-Thr(tBu)-O
~1 cH3
Br \ I N
40b ~NBoc
second eluted
i
OH ~Br
40a NaOH, MeQH ~ N O N
CH3 NaH _
Br ~ N ~ ~1 CH3
39a ~NBoc Br \ I N
Enantiomer A ~NR2a
41 a. R2a = Bo~
42a. R2a = H TFA
O N
COOH
Me~. Me ~ I ~1 CH3
N:. N Br ~ N H3C ~N1
42a ---
43a ~N ~ N
EDCI/HOBt
Enantiomer A O CH3
A solution of alcohol 39ab (660 mg, 1.41 mmol), Boc-Thr(t-Bu)-OH
(413 mg, 1.50 mmol), DEC (290 mg, 1.50 mmol) and DMAP (190 mg, 1.55
mmol) in anhydrous CH2C12 (5 ml) was stirred overnight at RT. The
reaction mixture was poured into aqueous saturated NaHC03, extracted
with CH2C12, and dried over Na2S04. The residue obtained after
concentration of the solvent was subjected to flash chromatography over
silica gel (eluting with CH2C12/acetone, 9:1 ) to afford, in order of elution:
(i)
first 40a (391 mg, 38%), as a white foam; (ii) second 40b (391 mg, 38%),
as a white foam.
To a solution of diastereoisomer 40a (391 mg, 0.54 mmol) in CH30H
(3 ml) was added NaOH (110 mg, 2.75 mmol; 5 equiv.) and the solution
was stirred at 65 °C for 3 h. The final mixture was then poured into
aqueous 0.1 N NaOH and extracted with CH2C12 to yield 39a (Enantiomer
A) (246 mg, 98%) as a white foam. (Following the same procedure, 40b
gave 39b (Enantiomer B). 40a gives 43a (Enantiomer A) and 40b gives
43b (Enantiomer B.)).
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-36-
A solution of alcohol 39a (210 mg, 0.45 mmol), NaH 60% in mineral
oil (23 mg, 0.96 mmol), and 2-bromopyridine (60 NI; 0.62 mmol) in
anhydrous DMF (1.5 ml) was stirred 2 h at 75 °C. The reaction mixture
was
poured into aqueous sat'd NaHC03, extracted with CH2C12, dried over
Na2S04 and purified by flash chromatography over silica gel (eluting with
CH2C12/AcOEt/EtgN, 60:40:0.5 to 40:60:0.5) to afford 41a (143 mg, 59%).
Removal of the Boc-protecting group in 41a (93 mg, 0.17 mmol)
proceeded as for 34b to provide 42a (68 mg, 91 %), as a white foam.
The amine 42a (50 mg, 0.11 mmol) was coupled with 4,6-dimethyl-
pyrimiaine-5-carboxylic acid following the conditions described for the
synthesis of 35 to yield 43a (28 mg, 44%). ~ H-NMR (300 MHz, CDCIg) 8
8.92 (s, 1 H), 8.02 (m, 1 H), 7.51 (m, 1 H), 7.51 (br t, J = 8.4 Hz, 1 H),
7.41 (d,
J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz, 2H), 6.78 (m, 1 H), 6.73 (m, 1 H), 5.78
(m, 1 H), 4.19 (m, 1 H), 3.41 (m, 1 H), 3.36 (m, 1 H), 2.94 (m, 1 H), 2.78 (m,
1 H), 2.44 and 2.46 (s, 3H), 1.65-2.15 (m, 5H), 1.15-1.50 (m, 5H), 0.90 (s,
3H) ); HRMS (MH+) 578.2140.
The following compounds were prepared via similar methods:
R3
O
~~ CH3
R6 w N
N R2
O
wherein R3. R6 and R2 are as defined in the table:
Ex. Enantiome R6 R3 R2 HRMS
(MH+) found
r
4A A Br ~ N H C ~ CH3 577.2172
3
~ .N
4B B Br ~ N H C ~ CH 577.2162
3 ~ 3
~ ,N
4C B Br ~ N H C~CH 578.2119
3 i ~ 3
NON
4D A F3C0- I ~ H3C i~ CH3 584.2864
N
NvN
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-37-
4E B F3C0- ~ ~ H C~CH 583.2862
~t,t N 3 I \ 3
NON
4F A F3C0- \ N CH3 \ CH3 583.2904
~ ~J
4G A F3C0- \ N CH \ CH3 599.2857
~ ~J
4H A F3C0- ~ N H ~ CH 598.2994
3~ 3
INIY_ IN
CH3
41 B F3C0- \ N H C ~ CH 598.3000
3 ~ 3
~YN
CH3
4J A CI \ N CH3 \ CH3 534.2639
~ ~J
4K A CI ~ N H3C' H3 548.2784
f~Y N
CH3
4L B CI \ N CH3 \ CH3 534.2644
~ NJ
4M B CI ~ N H3C~H3 548.2784
NYN
CH3
4N A F3C0- t \ H C~CH 599.2947
N 3 ~ \ 3
N ~. N
NH2
40 B FgCO- ~ ~ H C~CH 599.2947
N 3 ~ \ 3
N~ N
NH2
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-38-
Additional data for compounds of Example 4:
Ex. 1 H-NMR (300 MHz'H NMR (CDC13))
4G 8.05 (m, 1 H), 7.97 (s, 2H), 7.53 (t, J = 7.5 Hz,
1 H), 7.41 (d, J = 8.4
Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H), 6.81 (t, J = 6.4
Hz, 1 H), 6.76 (m,
1 H), 5.87 (m, 1 H), 4.19 (m, 1 H), 3.30-3.50 (m,
2H), 2.99 (m, 2H),
2.79 (m, 1 H), 2.20 and 2.22 (s, 3H), 1.70-2.15 (m,
5H), 1.15-1.50
m,5H,0.91 s,3H
41 8.03 (m, 1 H), 7.53 (m, 1 H), 7.39 (d, J = 8.4 Hz,
2H), 7.14 (d, J = 8.4
Hz, 2H), 6.79 (t, J = 6.8 Hz, 1 H), 6.73 (m, 1 H),
5.87 (m, 1 H), 4.19
(m, 1 H), 3.42 (m, 1 H), 3.37 (m, 1 H), 2.98 (m,
2H), 2.80 (m, 1 H),
2.41 and 2.43 (s, 3H), 1.90-2.15 (m, 3H), 1.70-1.90
(m, 2H), 1.20-
1.50 m, 5H , 0.91 s, 3H
Example 5
HgCO~N N~OCHg
I I
~N Me ~ ~N Me
Br Br
~N O ~N O
Z-isomer ~ ~ E-isomer
and
1 ) Trifluroacetic anhydride (TFAA) (300 ml) is added to isonipecotic
acid (96 g) at 0°C and the reaction mixture is heated at reflux for 4h.
Excess TFAA is removed under vacuo, the reaction mixture is taken up in
EtOAc, washed with water and concentrated to give 160 g of the amide. 50
g of this amide is treated with SOC12 (300 ml) and the reaction mixture
heated at reflux overnight. Excess thionyl chloride is then removed under
vacuo to give 54 g of the acid chloride.
2) AIC13 (11 g) is added slowly to a solution of the product of step 1 (10
g) in bromobenzene (40 ml) at ambient temperature and the reaction
mixture is heated at reflux for 4 h. It is then cooled and poured into a
mixture of conc. HCI and ice, and the product is extracted with EtOAc. The
organic layer is separated and washed with water, half saturated NaHC03
solution and concentrated to give 16.21 g of the desired ketone.
3) The product of step 2 (16.21 g) is dissolved in toluene (200 ml)
containing ethylene glycol (25 ml) and p-toluenesulfonic acid (0.5 g). The
reaction mixture is heated at reflux with azeotropic removal of water until no
further water is collected. The reaction mixture is concentrated to give 17.4
g of the desired ketal.
CA 02371587 2004-07-22
WO 00/66559 PCT/US00/11633
-39-
4) The crude product of step 3 (17.4 g) is dissolved in CHgOH (1C)Oml)
and to this is added water (25 ml) and K2COg (12 g) and the reaction
mixture is stirred at ambient temperature overnight. The reaction mixture is
diluted with water and extracted with EtOAc. The organic layer is
separated, washed with water and brine, and concentrated to give 12.55 g
of the desired amine.
5) To a stirred solution of the product of step 4 (7.2 g, 23 mmol) and N-
BOC-piperidine-4-one (4.8 g, 24 mmol) in 1,2-dichloroethane (20 ml) is
added titanium isopropoxide (6.7 ml, 32.3 mmol) and the mixture is stiirred
for 12 h at RT. The reaction mixture is concentrated and a 1.0 M solution
of diethyl aluminium cyanide (35 ml) is added at RT and stirred for 3 h. The
reaction mixture is then diluted with EtOAc, quenched with water (5 ml) and
stirred for 2 h. The mixture is then filtered through Celite and the resulting
filtrate is concentrated and chromatographed with 30 % EtOAc/hexanes to
afford 7.3 g (63%) of the desired cyanide.
6) To a .stirred solution of the product of step 5 (7.3 g, 14.03 mmol) in
THF (100 ml) is added a 3.OM solution CH3MgBr in Et20 (14.0 ml, 42
mmol) at RT' and the mixture is stirred for 2 h. The reaction mixture is then
quenched with saturated aqueous NH4C1 and extracted with CH2C12. The
20 extracts are concentrated to afford 7.0 g of desired methylated compound.
7) The crude ketal of step 6 is dissolved in EtOAc (100 ml) and 6 hl HCI
(40 ml) and conc. HCI (10 ml) is added and the mixture stirred at RT for 24
h. The reaction mixture is then neutralised with 20%NaOH and extracted
with EtOAc, dried and concentrated to yield 5.0 g (98%) of amine.
25 8) To a stirred solution of the product of step 7 (5.0 g, 13.6 mmol) in
Et20 (200 ml) is added 10% NaOH (50 ml) and BOC20, and the mixture is
stirred at RT overnight. The layers are separated and the organic IayE~r is
washed with brine, dried, concentrated and chromatographed with 20',x°
EtOAc/hexanes to yield 5.1 g (79%) of the desired product.
30 9) To a stirred solution of the product of step 8 (1.5 g, 3.22 mmol) in
CH30H (50 ml) is added sodium acetate (5.0 g, 47 mmol) and O-Methyl
hydroxylamine hydrochloride and the mixture is stirred at RT for 24 h. The
resulting mixture is then poured into aqueous NaOH and extracted with
CH2CI2. The combined extracts are dried, concentrated and
35 chromatographed to yield 1.5 g (94%) of oxime as a mixture of E and :'_
isomers.
10) To a stirred solution of the product of step 9 (1.5 g, 3.0 mmol) in
CH2CI2 (10 ml) is added TFA (3 mL) and the mixture is stirred at RT for 2 h.
* trade-mark
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-40-
The reaction mixture is concentrated and poured into 10% NaOH and
extracted with CH2C12. The combined extracts are dried concentrated to
afford 1.2 g (100%) of amine.
11 ) To stirred solution of the product of step 10 (1.3 g, 3.2 mmol) in
CH2C12 is added 2,6-dimethylbenzoic acid (0.74 g, 4.96 mmol), EDCI (0.94
g, 4.94 mmol), DIPEA (0.84 g, 6.58 mmol) and HOBT (0.66g, 4.94 mmol)
and the mixture is stirred for 12 h at RT. The reaction mixture is quenched
with NaHC03 and extracted with CH2C12. The combined extracts are dried
and concentrated to yield 1.6 g of oxime as a mixture of E and Z isomers.
The isomers are separated by chromatography by eluting withCH2C12:Et20
(4:1 ) to afford 0.77 g of E isomer and 0.49 g of Z isomer.
E isomer: 300 MHz-~ H NMR (CDCIg) 8 7.5 (d, 2H), 7.23 (m, 2H), 7.10 (m,
1 H), 6.90 (d, 2H), 4.03 (m,1 H), 3.90 (s, 3H), 3.55 (m, 1 H), 3.20 (m, 3H),
3.00 (m, 3H), 2.82 (m, 1 H), 2.24 (s, 3H), 2.23 (s, 3H), 2.15 (m, 3H), 1.80-
1.20 (m, 5H), 0.92 (s, 3H); MS FAB+ observed= 526.2070; estimated =
526.2069
Z isomer: 300 Mhz -~ H NMR (CDC13) 8 7.50 (d, 2H), 7.15 -6.95 (m, 5H),
4.15 ( m, 1 H), 3.80 (s, 3H), 3.45 (s, 3 ), 3.25 (s, 3H), 3.00 (m, 2H), 2.24
(s,
3H), 2.25 (s, 3H), 2.10 (m, 2H), 1.80- 1.50 (m, 7H), 0.92 (s, 3H);
MS FAB+ observed= 526.2072; estimated = 526.2069.
The following compounds were prepared via similar methods:
X
R6 w ~ N
CH3
~N O
R2
wharain X R6 anrl R2 are as defined in the table:
Ex. R6 X R2 HRMS
MH+ found
~OCH3 ~~"'' 529.1017
gr ~ NH2
H3
5A C
(mixture - I
E/Z) -
gr N,OCH3 ~~~- 549.1023
5B ii CI ~ NH2
(mixture -C
E/Z)
gr CH3CH20'N H3C ~ CH3 542.2210
5C
-C-
5D gr N,OCH3 ~~~~ 549.1011
ii CI ~ NH2
-C
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-41 -
5E gr ~.OCH3 ~~~~' 529.1128
-C- Hs I \ NH2
i
5F gr H3C0~ """ 530.1020
N H3C ~ OH
-C- ~ i
5G gr H3C0~ ''w' 529.1017
N H3C \ NH2
-C- I ~
5H gr CHsCH20\ ~~~~ 542.1997
N H3C ~ OH
ii
-C- ~ i
51 Br CHsCH20~ H 1~~' CH 541.2178
N 3 \ 3
-C- I . N
5J gr H3CO~N H3C ~ CH3 527.2787
-C- I N
5K gr CHsCH20~ ~~~~ 543.1000
iN H3C ~ CH3
-C- ~ . N.0 _
5L Br H3C0~~ H C ~~CH 528.1971
3 \ 3
-C- N.~ N
5M Br iOCH2CH3 '""' 541.2194
H3 \ CH3
I N
-C-
5N Br CHsCH20~IN H3C ~~CH3 542.2132
-C- N.. N
50 gr CH3CH20~N C ~ C~ 583.1061
-c- I N'~
5P gr CFsCH20~ H '""' CH 595.1895
3 \ 3
-C- I . N
5Q gr CFsCH20IN H3C i~CH3 596.1831
-C- NON
5R gr CHsCH20~ """ 541.2188
'N H3C~CH3
-C-
N
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-42-
S gr CH3CH20~ ~~~ 597.4911
N C ~ I
"
-C-
O
5T Br H3C0~ C '~"" CI 569.0909
I
-C-
5U Br CI"13(CH2)2O~ H C ~ CH 571.2270
3 ~ 3
-C-
5V Br CH3(CH2)20~IN H3CyCH3 556.2291
-C- N.~ N
5W gr CH3CH20~ H C ~ CH 557.2119
3 I \ 3
N
-C- N
i
0
5X gr CHsCH20\ °~~~ 557.2124
Hs ~ \ Hs
-C- N i
OH
5Y Br H3~~O H C ~ CH 570.2454
H3C ~ 3 ~ 3
Ii N~ N
-C-
5Z gr CHsCH20~ ~~~ 671.0058
N Br \ Br
-C-
5AA Br ~O~ H C ~ CH 568.2286
N 3 ~ \ 3
- NON
5BB Br H3C~-O H3C~CH3 556.2286
HsC \N NON
-C-
5CC gr HsCO~ """' 527.2015
'N H3C ~ \ CHs
-C- N
5DD Br CHsCH20~N \ gr 592.1000
" I
-C-
5EE Br HsCO~ gr ~' Br 656.9889
-C- N
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-43-
5FF gr CHsCH20~ ~~" 686.9989
N Br~ Br
-C- I ,'
O
5GG gr CHsCH20'N H3C i~CH3 556.2290
-C- NY N
CH3
5HH F3C- CH3CH20' H C ~ CH 546.3056
N 3 ~ \ 3
-C- N Y N
CH3
511 F3C- CH3CH20~ H C ~ CH 531.2956
3 I \ 3
-C- '
N
5JJ F3C- CHsCH20~ H C ~ CH 547.2902
3 I \ 3
C- '
N
i
0
5KK F3C- H3C0~ """' 517.2812
N H3C I \ CH3
-C- N
5LL Br H3CY0~ H3C \ CH3 555.2336
HsC N I '
-C- N
5MM Br ~O~ H C ~ CH 567.2327
3 ~ 3
N
-C- N
5NN gr CHs(CH2)20~N H3C \ CH3 555.2341
-C- N
500 gr CHsCH20'N H3C i~CH3 610.2016
-C- NY N
CF3
5PP F CO- CHsCH20~ ~~" 616.2746
N H3C~CH3
-C- NY N
CF3
5QQ F3C- CHsCH20' H C ~ CH 600.2788
N 3 ~ 3
-C- NY N
CF3
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-44-
5RR gr CH3CH20~ "r.~'' CHs 593.2131
.O
-C- N
5SS gr CHsCH20~ H C ~ CH 590.1995
3 ~ 3
-C-
NYN
SCHs
5~ gr CH3CH20~ '~°'"' ~ 627.1729
N H3C
-C- O_ N
CI
5UU gr CHsCH20~ H C ~ CH 556.218
3 I \ 3
N
-C-
OH
5VV gr H3C0~ ~"~' 542.2002
N HsC w CH3
-C-
OH
5WW gr CH3CH20~ H C ~ CH 555.2336
3 I \ 3
I
-C-
NH2
5XX gr CHsCH20~ H C ~ CH 655.287
3 I \ 3
-C-
HN-BOC
5YY gr CHsCH20~ "~"'' 566.2407
N
-C- ~ i CHs
5ZZ Br HsCO~ "~ 603.2349
HsC ~ ~ CHs
-C-
~I
'N
5AB gr CHsCH20~ '"""' 617.2488
N HsC ~ CHs
I I
-C-
~I
~N
5AC gr CHsCH20~ H C ~ CH 640.2868
3 \ 3
IN ~ /
-C-
NH~N~CH3
O CHs
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
- 45 -
Ari~iitinnal riata for compounds of Example 5:
Ex. 1H-NMR (300 MHz'H NMR (CDC13))
5J 7.50 (d, 2H), 7.15 -6.95 (m, 5H), 4.15 ( m, 1 H),3.80
(s, 3H), 3.45 (s,
3H), 3.25 (s, 3H), 3.00 (m, 2H), 2.24 (s, 3H), 2.25
(s, 3H), 2.10 (m,
2H , 1.80- 1.50 m, 7H , 0.92 s, 3H
5L 8.95 (s, 1 H), 7.53 (d, J = 8.4 Hz, 2H), 7.10 (d,
J = 8.4 Hz, 2H), 4.24
(m, 1 H), 3.81 (s, 3H), 3.98 (m, 2H), 2.75-3.00 (m,
3H), 2.48 (s, 3H),
2.45 (s, 3H), 1.99 -2.20 (m, 4H), 1.73 (m, 3H), 1.20-1.62
(m, 4H),
0.94 s, 3H
5N 8.92 (s, 1 H), 7.45 (d, J = 9.0 Hz, 2H), 7.10 (d,
J = 8.7 Hz, 2H), 4.21
(m, 1 H), 4.02 (q, J = 6.9 Hz, 2H), 3.98 (m, 2H),
2.75-2.92 (m, 3H),
2.46 (s, 3H), 2.41 (s, 3H), 1.90 -2.20 (m, 4H), 1.73
(m, 3H), 1.27-1.62
m, 4H , 1.15 t, J = 8.1 Hz, 3H , 0.93 s, 3H
Example 6
H3CO.N N.OCH3
F3C0 ~ N ~ I F3C0 \ N ~ I
N ~ N ~N ~ N
Z-isomer I ( E-isomer t
o and o
A) Preparation of intermediate 27 (Scheme 8 (R~ = CH3)).
1 ) 23 (40.0 g, 0.203 mol) is vigorously stirred in EtOAc (200 ml) and
concentrated aqueous HCI (80 ml) for 1.5 h. The solution is concentrated,
diluted with Et20 (300 ml) and H20 (150 ml), the aqueous layer is
separated and the organic layer is extracted once with H20 (20 ml).
Combined aqueous layers are concentrated and the residue is dried 24 h
under high vaccum to provide 26.7 g (84%) of a white solid. To this
hydrochloride and N-tent butoxycarbonyl-4-piperidone (43.8 g, 0.22 mol) in
anhydrous CICH2CH2C1 (80 mL) with 4 A molecular sieves, are
successively added DBU (33.2 ml, 0.22 mol) and titanium(IV) isopropoxide
(65.5 ml, 0.22 mol) at 0° C, the reaction mixture is allowed to warm to
RT
and is stirred overnight at RT. The mixture is then cooled to 0 °C and
diethylaluminum cyanide, 1 N in toluene (260 ml, 0.26 mol) is added with
vigorous stirring. The reaction is allowed to warm to RT and stirred an
additional 3 h, after which are added CH2C12 (300 ml), EtOAc (300 ml), and
Celite (50 g). The reaction mixture is cooled to 0 °C, water (40 ml)
is added
slowly with vigorous stirring and, after an additional 5 min. stirring at RT,
the excess of water is quenched with Na2S04. The final mixture is then
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-46-
filtered over Celite, evaporated and subjected to flash chromatography over
silica gel (eluting with Hexanes/EtOAc, 8:2), to provide 50.3 g (83%) of 24
as a colorless oil which solidifies upon standing.
2) To a solution of 24 (27.7 g, 90.6 mmol) in anhydrous THF (200 mL)
at 0 °C is slowly added CH3MgBr 3 M in Et20 (91 ml, 3 equiv.) with
vigorous stirring. After the addition, the reaction is allowed to warm to RT
and stirred 3 h. The reaction is then poured into aqueous saturated NH4C1,
extracted with Et20 (4 times), washed with brine, dried over Na2S04, and
concentrated to give 27.1 g (100%) of 25 as a colorless oil.
3) To a solution of 25 (11.6 g, 39.3 mmol) in anhydrous THF (50 ml) at
0 °C is slowly added BH3'S(CH3)2 2 N in THF (14 ml, 28 mmol) and the
solution is stirred 2 days at RT. The final mixture is concentrated to ca. 50
ml and slowly poured into ice-cooled EtOH/THF 1:1 (50 ml). After 15 min.
at 0 °C, 50 ml of a pH 7 buffer solution are added, followed slowly by
30%
H202 aqueous solution (50 ml). The reaction mixture is stirred overnight at
RT, diluted with 1 N NaOH and extracted with CH2C12. Combined organic
layers are dried over Na2S04, concentrated, then subjected to flash
chromatography over silica gel (eluting with EtOAc/EtOH, 8:2) to yield 9.69
g (79%) of 26 as a colorless oil.
4) A solution of 26 (11.2 g, 35.8 mmol) and N methylmorpholine N
oxide (4.67 g, 39.4 mmol) in anhydrous CH2C12 (100 ml) is stirred 1 h at
RT, cooled to 0 °C, and TPAP (885 mg) is added portionwise. The
reaction
is allowed to warm to RT and stirred 1 h. Additional N-methyl-morpholine
N-oxide (1.30 g, 11 mmol) and TPAP (300 mg) are then added to drive the
reaction to completion after 1 h. The reaction mixture is filtered over
Celite,
concentrated, then subjected to flash chromatography over silica gel
(eluting with CH2C12/acetone, 8:2 to 7:3) to provide 5.91 g (53%) of 27 as a
yellow oil.
B) Preparation of title compounds of Example 6.
1 ) A solution of 1-bromo-4-(trifluoromethoxy)-benzene (4.20 ml, 28.0
mmol) in anhydrous THF (100 mL) is cooled to -78 °C and n-BuLi 2.5 N in
hexanes (11.2 ml, 28.0 mmol) is added via syringe. The reaction mixture is
allowed to warm to -50 °C for 10 min, cooled to -78 °C, and a
solution of
aldehyde 27 (6.20 g, 20.0 mmol) in anhydrous THF (15 ml) is added
dropwise. After stirring 30 min at -78 °C, then 30 min at -20
°C, the solution
is poured into half-brine and extracted with CH2C12 (3 x 100 ml). Combined
organic layers are dried over Na2S04, and concentrated to give 8.85 g
(94%) of an alcohol as a yellow oil.
CA 02371587 2001-10-24
WO 00/66559 - 47 - PCT/US00/11633
2) To a solution of the product of step 1 (8.85 g, 39.3 mmol) in CH2C12
(100 ml) at 0 °C is added Dess-Martin periodinane (19.70 g, 2.5 equiv.)
and
the reaction mixture is stirred 2 h at RT. An additional 8.0 g of Dess-Martin
periodinane is added and the reaction is stirred for an additional
4 h. The solution is poured into a 1:1 mixture of aqueous saturated
NaHCOg and aqueous saturated Na2S20g (200 ml), stirred 10 min,
extracted with CH2C12, and dried over Na2S04. The residue obtained after
concentration of the solvents is purified by flash chromatography over silica
gel (eluting with hexanes/EtOAc, 7:3) to yield 5.48 g (63%) of the ketone as
a yellow oil.
3) A solution of the product of step 2 (2.85 g, 6.05 mmol), HONH2~HC1
(2.08 g, 30 mmol), and AcONa (2.46 g, 30 mmol) in EtOH (50 mL) is
heated at reflux under N2 for 4 h. After evaporation of the solvent, the
residue is taken up in aqueous 0.1 N NaOH and extracted with CH2C12.
The residue obtained after evaporation of the solvents is subjected to flash
chromatography over silica gel, to afford first the E-hydroxime (eluting with
CH2C12/EtOAc, 7:3; 0.84 g; 29%), then the Z-hydroxime (eluting with
CH2C12/EtOAc 1:1; 1.10 g; 37%), both products as white solids.
4) To a suspension of Z-hydroxime (0.89 g, 1.84 mmol) in anhydrous
DMF (5 ml) is slowly added KHMDA 0.5 N in toluene (4.0 ml, 2.02 mmol) at
0 °C, leading to the appearance of a yellow solution. After 2 min. at
this
temperature, dimethylsulfate (350,u1, 3.7 mmol) is slowly added and the
solution is allowed to warm to RT and stirred 1 h. The mixture is poured
into aqueous 0.1 N NaOH, extracted with CH2C12, and dried over Na2S04.
The residue obtained after concentration of the solvents is purified by flash
chromatography over silica gel (eluting with hexanes/EtOAc, 75:25) to
afford 0.55 g (62%) of the Z-methoxime as a slighly yellow oil.
5) A solution of Z-methoxime (0.59 g, 1.18 mmol) in anhydrous CH2C12
(6 ml) and TFA (3 ml) is stirred 1 h at RT. After concentration, the residue
is taken up in aqueous 1 N NaOH, extracted with CH2C12, dried over
Na2S04 and concentrated to give 0.47 g (100%) of the free amine as a
white foam.
6) A solution of the product of step 5 (470 mg, 1.18 mmol), 2,4-
dimethylnicotinic acid (220 mg, 1.45 mmol), DEC (280 mg, 1.45 mmol),
HOBT (243 mg, 1.80 mmol) and N-methylmorpholine (0.33 ml, 3.0 mmol) in
anhydrous DMF is stirred 14 h. After concentration, the residue is taken up
in aqueous 0.1 N NaOH, extracted with CH2C12, and dried over Na2S04.
The residue obtained after concentration of the solvent is purified by flash
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-48-
chromatography over silica gel (eluting with CH2C12/acetone, 7:3 to 1:1 ) to
afford 640 mg (100%) of a colorless oil.
~ H-NMR (400 MHz, CDCIg) 8 8.35 (d, J = 7.8 Hz, 1 H), 7.25 (AB system,
4H), 6.98 (d, J = 7.8 Hz, 1 H), 4.22 (m, 1 H), 3.82 (s, 3H), 3.43 (m, 1 H),
3.33
(m, 1 H), 2.99 (m, 2H), 2.85 (m, 1 H), 2.49 (s, 3H, atropisomer a) and 2.51
(s,3H, atropisomer b), 2.26 (s, 3H, atropisomer a) and 2/28 (s, 3H,
atropisomer b), 1.95-2.21 (m, 3H), 1.20-1.90 (m, 7H), 0.92 (s, 3H).
HRMS (M+H+) 533.2747.
Following steps B-4, B-5, and B-6 using the E-oxime yields the
corresponding E-methoxime product.
The following compounds are prepared via similar procedures:
R40
N
I
/ ~1 CH3
R6 ~ ~ N
N ~O
R2
.~rhc~roin C:4 Gt6 anrl R2 ara aS riefined in the table:
. Ex. R6 R4 R2 HRMS
. MH+ found
6A Br H3~~ H C ~ CH3 554.3000
3
Hs
/
6B Br Hs~~ H3~cw~ 555.2335
~~-IN
6C Br Hs~~ H ~ OH 556.2175
H3C 3 ~ /
6D Br H3c ~ cw3 571.2284
H3C0~,.~''' ~ ,N
6E Br ~ 570.2331
H3C0~,.~''' H3C I ~ CH3
/
6F Br H3~c~ 569.1000
~ ~N
6G F3CC- F3~ H3~c~ 601.2628
~ ~N
6H F3CC- F3~ w,~c~cr+~ 617.2549
I . N.~o
CA 02371587 2001-10-24
WO 00/66559 _ 4g _ PCT/US00/11633
61 FgCO- -CHg H C ~ CH 534.2708
3 I \ 3
NON
6J F3C0- F3~ Hs ~ CH 602.2465
I~
602.2579
6K F3C0- FsC\
H3C~CH3
I
NON
6L F3C0- w~cr~ 589.3013
I ' ~'o
6M CI CHgCH2- Hs ~ CHs 513.2633
~N~
6N CI CH3- H C ~ CH 483.2516
3 ~ ~ 3
~N
60 F3C- CHg- ,..,~~c,~ 533.2758
I ''\T~'o
6P CI CH3CH2- H C ~ CH 487.2683
3 ~ ~ 3
~N
6Q CI CHgCH2- ~~c~ 513.2642
I ''-I~''o
6R CI CH3CH2- ~ 498.2633
H3C~CH3
I
NON
6S F3C- CH3- ~ 518.2749
H3C~CH3
I
NON
6T CI CH3CH2- CI ~ CI 537.1603
I
6U F3C- CHg- CI ~Y CI 557.1680
I N/J
6V F3C- CHgCH2- CI ~ CI 571.1838
N
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-50-
6W CI CH3CH2- CI 'M" I 555.8401
N
_a
6X CI CH3CH2- H3 ~ CH3 497.2682
~NJ
6Y F3C0- CH3- ~ 548.2853
H3C~CH3
1
N~ N
CH3
6Z F3C0- CH3CH2- ~ 562.3017
H3C~CH3
I
NY N
CH3
6AA F3C0- CH3CH2- ~ 563.2939
H3C~CH3
I
N~N
NH2
Additional data for compounds of Example 6:
Ex. ~H-NMR (300 MHz'H NMR (CDCIg))
6F 8.31 (d, 1 H), 7.51 (d, 2H), 7.10 (d, 2H), 6.95 (d,
2H), 4.20 (m, 2H),
3.40 (d, 2H), 3.30 (m, 2H), 3.35 (m, 3H), 2.80-3.05
(m, 5H), 2.45 (d,
3H), 2.25 (d, 3H), 1.25-2.20 (m, 10H), 0.50 (m, 2
H), 0.22 (m, 2H),
0.90 s, 3H
6G 8.34 (d, J = 5.1 Hz, 1 H), 7.24 (br s, 4H), 6.96 (d,
J = 5.1 Hz, 1 H),
4.33 (q, J = 8.6 Hz, 2H), 4.13 (m, 1 H), 3.45 (m,
1 H), 3.30 (m, 1 H),
2.98 (m, 2H), 2.82 (m, 1 H), 2.46 and 2.49 (s, 3H),
2.41 (m, 1 H), 2.24
and 2.27 (s, 3H), 2.10 (m, 2H), 1.96 (m, 1 H), 1.15-1.90
(m, 7H), 0.92
s, 3H
61 8.92 (s, 1 H), 7.23 (br s, 4H), 4.11 (m, 1 H), 3.79
(s, 3H), 3.30-3.45 (m,
2H), 2.97 (m, 2H), 2.81 (m, 1 H), 2.45 and 2.42 (s,
6H), 2.40 (m, 1 H),
1.90-2.20 m, 3H , 1.15-1.90 m, 7H , 0.92 s, 3H
Example 7
Alternate synthesis of the compounds of Example 6.
1 ) The product of Example 6, step B-2 (566 mg, 1.20 mmol) is treated
with H3CONH2~HC1 using conditions similar to those shown in Example 6,
CA 02371587 2001-10-24
WO 00/66559 _ 51 _ PCT/US00/11633
step B-3. The resulting crude mixture of Z- and E-methoximes is separated
on a preparative silica gel TLC plate (eluting with hexanes/ EtOAc, 80:20)
to afford, in order of elution, first the E-methoxime (175 mg; 29%), then the
Z-methoxime (175 mg; 29%), both products as oils.
2) The Z-methoxime (75 mg; 0.15 mmol) of step 1 is deprotected
following conditions similar to those shown in Example 6, step B-5 and the
resulting free amine (46 mg) is directly subjected to amidation with 2,4-
dimethylnicotinic acid using conditions similar to those shown in Example 6,
step B-6 to yield 50 mg (82%) of a colorless oil.
The following compounds are prepared via similar procedures:
R40~ N
I ~ N Me
R
N~O
R2
whArain R4 R6 and R2 are as defined in the table:
Ex. R6 R4 R2 HRMS
MH+ found
7A FgCO- CH3- H3C ~ CH3 532.2795
7g F3C0- CH3- CI ~ NH2 553.2192
7C FgCO- CH3- H3C ~ NH2 533.2730
7p FgCO- CHgCH2- """' 546.2940
H3C ~ CH3
I i
7E FgC- CHg- """' 516.2833
H3C ~ CH3
I i
7F F3C0- CH3- H3 '"~ OH 534.2571
7G FsC- CH3- CI ~ NH2 537.2234
isomer) I i
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-52-
7H FgC- CHg- CI ~ NH2 537.2234
FgC- CHg- "''"' 537.2234
H3C ~ NH2
i
567.2362
FgCO- CH3CH2- CI ~ NH2
7K FgC- CH3- H3c~cr+~ 517.2812
I~N
F3C- CHgCH2- H3 ""~ OH 532.2787
7M F3C0- CH3CH2- H3~c,.~ 547.2888
I.N
7N F3CO- ~~~~ 572.3093
H3C I ~ CH3
i
7p FgCO- CHgCH2- H3C ~ OH 548.2732
7p FgC- CHg- H3~c~ 517.2831
(E I ..''N
isomer
7Q FgCO- CH3- ,~~c,~ 549.2686
. I ,'\~N'''o
7R F3C0- CHgCH2- '""r 590.2854
HsC i w O~O
CH3
7g F3C- CH3CH2- H3~c,~ 531.1002
~~. TN
7T F3C- CHgCH2- ,..,~~c~ 547.1348
I ''~1~'''0
532.2784
7U FsCO- CH3- H3C I ~ CH3
isomer)
7V F3CO- ~~~~ 576.3049
H3C0~,.~'' H3C I ~ CHs
i
7W F3C0- CH3CH2- ,~~c,~ 563.2855
'~ I ''~~~'''o
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-53-
7X FgCO- H3~~~ 573.3052
~~.TN
7Y F3C0- '""' 574.2889
H3 ~ OH
I~
7Z FgCO- CFgCH2- CI ~ CI 641.1537
i N'J
7AA F3C0- CHg- '~"" 573.1638
CI ~ I
N
7gg F3C0- CHgCH2- '""" 587.1821
CI ~ I
N
7CC F3C0- CH3CH2- """' 548.2861
H3C~CH3
NON
7DD FgCO- CHg- CI ~ CI 589.1610
I ~J
7EE F3C0- CH3CH2- '""'' 603.1748
CI ~ CI
7FF F3C0- CH3(CH2)2- '"'"' 562.3030
H3C 11 'I H3
NON
7GG F3C0- CH3(CH2)2- CI "'~ CI 617.1918
N'
7HH F3C0- CH3(CH2)2- ,..~~o~ 577.3019
I~'\1~~'~0
Additional data for compounds of Example 7:
Ex. ~H-NMR (300 MHz'H NMR (CDC13))
7H 7.55 (d, 2H), 7.30 (d, 2H), 7.15 (t, 1 H), 6.75 (d,
1 H), 6.60 (d, 1 H),
4.25 (m, 2H), 3.80 (s, 3H), 3.40 (m, 2H), 2.80-3.20
(m, 3H), 2.40 (m,
1 H , 1.40-2.20 m, 13H , 0.90 s, 3H
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-54-
7K 8.31 (d, 1 H), 7.61 (d, 2H), 7.31 (d, 2H), 6.95 (d,
2H), 4.30 (m, 2H),
3.80 (3, 2H), 3.20-3.50 (m, 2H), 2.75-3.05 (m, 3H),
2.45 (d, 3H), 2.25
d, 3H , 1.45-2.20 m, 11 H , 0.92 s, 3H
70 8.11 (d, J = 6.8 Hz, 1 H), 7.25 (br s, 4H), 6.94 (d,
J = 6.8 Hz, 1 H),
4.16 (m, 1 H), 3.75 (s, 3H), 3.20-3.45 (m, 2H), 2.85-3.00
(m, 3H), 2.41
(d,
J = 11.6 Hz, 3H), 2.45 (m, 1 H), 2.20 (d, J = 11.6
Hz, 3H), 1.85-2.20
m, 3H , 1.15-1.85 m, 7H , 0.88 s, 3H
7R 7.13-7.30 (m, 5H), 7.14 (m, 1 H), 6.95 (m, 1 H), 4.13
(m, 1 H), 4.03 (q,
J = 7.1 Hz, 2H), 3.15-3.50 (m, 2H), 2.86-3.10 (m,
2H), 2.80 (m, 1 H),
2.39 (m, 1 H), 2.15-2.30 (m, 6H), 1.85-2.15 (m, 3H),
1.10-1.85 (m,
7H , 1.28 t, J = 7.1 Hz, 3H , 0.88 br s, 3H
7S 8.31 (d, 1 H), 7.61 (d, 2H), 7.32 (d, 2H), 6.95 (d,
2H), 4.25 (m, 2H),
4.05 (q, 2H), 3.20-3.50 (m, 2H), 2.80-3.15 (m, 3H),
2.45 (d, 3H), 2.25
d, 3H , 1.45-2.20 m, 9H , 1.20 t, 3H , 0.90 s, 3H
Example 8
HgCO.N
I
~~ Me
W N
H3CS02 I
~N W N
O
1 ) To a stirred solution of the product of Example 5, step 8 (0.500 g,
1.07 mmol) in DMF (25 ml) is added sodium methylmercaptide (0.113 g,
1.62 mmol) and the mixture is heated to 70° C for 12 h. The reaction
mixture is then cooled to RT, diluted with Et20, washed wifh brine, dried
and concentrated to yield 0.437 g (97%) of sulfide.
2) A solution of the product of step 1 (1.00 g; 2.31 mmol),
H3CONH2~HC1 (3.80 g, 46.2 mmol), and AcONa (3.79 g, 46.2 mmol) in
EtOH (30 ml) is heated at reflux under N2 for 4 h. After evaporation of the
solvent, the residue is taken up in aqueous 0.1 N NaOH and extracted with
CH2C12. The residue obtained after evaporation of the solvents is
subjected to flash chromatography over silica gel, to afford first the E-oxime
(eluting Et20/CH2C12, 1:4; 0.45 g; 24%), then the Z-oxime (0.25 g, 15%).
3) To a solution of Z-oxime (0.250 g, 0.543 mmol) of step 2 in CH30H
(5 ml) is at 0° C is added oxone (1.00 g, 1.627 mmol in 5 ml of CH30H)
and
the mixture is stirred at 0°C for 4 h. The reaction is then quenched
with
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-55-
10% NaOH, concentrated, poured into water (10 ml) and extracted with
CH2C12, dried and concentrated to yield 0.220 g (82%) of sulfone.
4) To a stirred solution of the product of step 3 (0.300 g, 0.608 mmol) in
CH2C12 (5 ml) is added TFA(1 ml) and the mixture is stirred at RT for 2 h.
The reaction mixture is concentrated, poured into 10% NaOH and extracted
with CH2C12. The combined extracts are dried and concentrated to afford
0.240 g (100%) of amine.
5) To stirred solution of the product of step 4 (0.45 g, 0.114 mmol) in
CH2C12 is added 2,6-dimethylnicotinic acid (0.26 g, 0.172 mmol), DEC
(0.33 g, 0.172 mmol), N,N,N-diisopropylethylamine (DIPEA) (0.2 ml) and
HOBT (0.24g, 0.172 mmol) and the mixture is stirred for 12 h at RT The
reaction mixture is quenched with NaHC03, extracted with CH2C12, dried,
concentrated and purified by preparative chromatography (20%
EtOH/EtOAc) to afford 0.046 g (76%) of Z-oxime amide.
300 MHz -1 H NMR (CDC13) b 8.32 (d, 1 H), 7.95 (d, 2H), 7.40 (d, 2H), 6.95
(d, 1 H), 4.20 ( m, 1 H), 3.82 (s, 3H), 3.30-3.45 (m, 3H), 3.10 (s, 3H), 2.80-
3.00 (m, 3H), 2.50 (d, 2H), 2.25 (d, 2H), 1.30- 2.20 (m, 12H), 0.92 (s, 3H).
The following compounds were prepared in a similar manner:
X
s ~ I ~N CHs
R
N ~O
R2
wherein X. R6 and R2 are as defined in the table:
Ex. R6 X R2 HRMS
MH+ found
N,OCH3 ~ 526.2753
S H3C
CH3
8A O; ii w
(mixture~ -C- ( ,
CH3
E/Z
N,OCH3 ~~~~ 547.2135
CI
NH
8B O;S~CH -C- I ~
3 2
Br CHsO~ ~~"' 549.2133
8C N CI ~ NH2
i
-C- ~ i
8D 0%S~~ CH3CH20 N H C ~ CH 541.2849
s
s
O CHs (
-C- . N
8E Oa CH3CH2C~ ~~~~ 557.2798
~'~
S Hs ~ CH3
\
3
CH I
-C- N_~
O
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-56-
8F O~~ ~'~ CH30~ ~~"' 543.2641
CHs
Hs
O ~S~CH N I ~
s
-C- . N
8G O~ ~~ CHsO~ ~~~' 527.2692
S CHs
Hs
~CH N I ~
O ~
s
-C- . N_~ O
8H F3C- CH3CH20 ~~~~ 532.2895
N H3C~CH3
-C_ NON
81 O~ ~'~ CH30~ ~~~~ 542.2796
,S N H3C~CH3
O, . i i
CHs -C- NON
Example 9
i
N CHs H3C
Br
N
OCI / \
Resin-bound i
N CH carbodiimide Br ~ N CH3
Br
~N O
~NH R2C02H
HOBT R2
Dissolve the starting amine (2.0 g , 5.7 mmol) in CHC13 (57 ml; _
Stock solution A - 0.1 M). Add 430,u1 of stock solution A (0.043 mmol) to a
slurry of 0.25 g (- 0.22 mmol ) of resin bound cardodiimide (prepared by
reacting Argopore-CI resin with 1-(3-dimethylaminopropyl)3-ethyl
carbodiimide in DMF at 100 C) in DMF (2 ml) in a polyethylene SPE
cartridge. To this mixture add 0.12 ml of a 1 M solution of 5-methyl-3-[2-
chlorophenyl]isoxazole-4-carboxylic acid in DMF (0.12 mmol), HOBT (86,u1
of a 0.5M solution in DMF) and DMAP (25 NI of a 0.05M solution in DMF).
Shake this mixture for 14 h, filter and add 0.3 g of Amberlyst-15 resin (~ 1.5
mmol) to the filtrate. Shake for 1 to 2 h, filter and wash the resin twice
with
each of the following solvents: THF, CH2C12 and CH30H, then wash with
THF and CH2C12. Treat the resin with 2M NH3 in CH30H (1 time for 30
min, and 1 time for 5 min.). Combine and concentrate the filtrates under
reduced pressure to afford the title compound. LCMS found MH+= 570,
572 (calculated MW 571 ); TLC Rf = 0.45 (CH2C12/CH30H/ NH40H
(95/5/0.5)).
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-57-
Using a similar procedure, the following compounds were prepared
Br ~ I N CH3
R2
wherein R2 is as defined in the table:
Ex. R2 Data TLC
Rf values
LCMS:
9A H3C ~ MH+ = 538.1 0.58
~ ~
~ Rt = 6.27
O_N min
9B ",.~'' NH2 MS m/e =
~ 475.2, 477.2
Electros
ra
( P Y)
"N,~,,CI LCMS:
9C H3C ~ \ / MH+ = 606 0.57
~~
O
CI
LCMS:
_ MH+ = 507.1 0.49
Rt = 6.39
min
gE LCMS:
MH+ = 497.1 0.48
Rt = 6.32
min
Example 10
O~N
~ ~I
Br' v N -N1
~N ~ N
O I
Step 1: To a solution of alcohol 39ab (406 mg; 0.87 mmol), 3-hydroxy-
pyridine (95.1 mg; 1 mmol) and PPh3 (262 mg; 1 mmol) in anhydrous THF
(2 ml) at 0 °C was added diethylazodicarboxylate (160 ml; 1 mmol) and
the
mixture was allowed to warm to RT overnight. The reaction was poured
into 5% aqueous NaHC03, extracted with CH2C12, and dried over Na2S04.
After concentration of the solvents, the resulting oil was purified by flash
chromatography over silica gel (eluting CH2C12/CH30H 97:3 to 95:5) to
afford the desired compound (290 mg; 61 %), as an oil.
Step 2: Removal of the Boc-protecting group of the product of step 1 (290
mg; 0.53 mmol) proceeded as in Example 2 to obtain the desired amine
(210 mg; 89%), as a white foam.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-58-
Step 3: The amine of step 2 (50 mg; 0.11 mmol) was coupled with 4,6-
dimethylpyrimidine-5-carboxylic acid following the conditions described in
Example 2 to obtain the title compound (32 mg; 49%) as a colorless oil:
i H-NMR (300 MHz, CDC13) 8 8.91 (s, 1 H), 8.20 (br s, 1 H), 8.10 (d, J = 4.5
Hz, 1 H), 7.43 (br d, J = 8.4 Hz, 2H), 7.14 (br d, J = 8.4 Hz, 2H), 6.95-7.10
(m, 2H), 4.75 (br d, J = 6.8 Hz, 1 H), 4.15 (m, 1 H), 3.44 (m, 1 H), 3.33 (m,
1 H), 2.95 (m, 2H), 2.79 (m, 1 H), 2.42 and 2.44 (s, 3H), 1.85-2.15 (m, 3H),
1.65-1.85 (m, 2H), 1.15-1.50 (m, 5H), 0.90 (s, 3H); HRMS (MH+)
578.2115.
Using similar procedures, compounds of the following structure were
prepared
R3
O'
CH3
Rs ~ ~ N
~N R2
O
wherein R3. R6 and R2 are as defined in the table:
Ex. R6 R3 R2 HRMS
MH+ found
10A CHgS02-\ I "3 I ~ c~ 592.2848
' ~'~o
10B Br ~ H3C (~ CH3
577.2166
10C Br
~ I F H3C i ~ CHs 595.2078
NON
10D F
~ I H3C~CH3 517.2992
NON
10E F ~ I H3C I~ CH3 516.3031
~N
10F F \ I w3~c~
532.2981
0
10G Br
w I F H3C i ~ CHs 595.2072
NON
10H CI
~ I CI H3C ~ ~ CHs 567.2308
NON
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-59-
101 F3C_ ~ I
\ I ~~~ 582.2955
0
10,1 CHgS02-
~ i H3C~CH3 577.2853
NvN
10K CH3S02- i
H3C~CH3 595.2764
NON
10L F3C0-
F H3C~CH3 601.2817
NON
10M F3C0- \ I H3C~CH3
CI Ti ~T 617.2514
NvN
lON CH3S02- I ~~~
H3C~CH3 611.2460
\ I N.~ N
100 CHgS02- F ~~~
H3C~CH3 595.2749
I i
\ NON
10P F3C-
~ I H3C ~ \ CHs 597.2951
NON
10Q FgCO-
i j H3C i \ CHs 583.2905
NON
10R F3CO- ~ o
I i ~ i ~~~ 598.2903
0
1OS F3C- I ~ H C ~ CH 601.2556
/ ~ 3 ~ 3
CI
NON
10T F3C- I \ H C ~ CH 585.2559
3 ~ \ 3
F
NON
10U F3C0- I N H 584.2860
C~CH
3
3
NON
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-60-
Additional data for compounds of Example 10:
Ex. ~H-NMR (300 MHz'H NMR (CDC13))
1 8.95 (s, 1 H), 7.46 (br d, J = 8.4 Hz, 2H), 7.17
OC (br d, J = 8.4 Hz,
2H), 6.86 (t, J = 9 Hz, 2H), 6.70-6.72 (m, 2H),
4.69 (br d, J = 6.4
Hz, 1 H), 4.19 (m, 1 H), 3.47 (m, 1 H), 3.37 (m,
1 H), 2.99 (m, 2H),
2.82 (m, 1 H), 2.47 and 2.50 (s, 3H), 1.90-2.15
(m, 3H), 1.65-1.90
m, 2H , 1.20-1.50 m, 5H , 0.93 s, 3H
1 8.17 (d, J = 6.8 Hz, 1 H), 7.28 (m, 2H), 7.18 (t,
OF J = 7.5 Hz, 1 H),
6.95-7.10 (m, 3H), 6.87 (t, J = 7.5 Hz, 1 H), 6.80
(d, J = 7.5 Hz,
2H), 4.80 (d, J = 6.8 Hz, 1 H), 4.17 (m, 1 H), 3.25-3.50
(m, 2H),
2.99 (m, 2H), 2.80 (m, 1 H), 2.43 (br s, 3H), 2.24
(br s, 3H), 1.65-
2.20 m, 5H , 1.15-1.50 m, 5H , 0.90 s, 3H
1 8.95 (s, 1 H), 7.32 (br d, J = 8.4 Hz, 2H), 7.23
OH (br d, J = 8.4 Hz,
2H), 7.08 (t, J = 8.1 Hz, 1 H), 6.80-6.90 (m, 2H),
6.68 (m, 1 H), 4.77
(br d, J = 6.8 Hz, 1 H), 4.19 (m, 1 H), 3.46 (m,
1 H), 3.37 (m, 1 H),
3.00 (m, 2H), 2.81 (m, 1 H), 2.47 and 2.49 (s, 3H),
1.90-2.15 (m,
3H , 1.65-1.90 m, 2H , 1.20-1.50 m, 5H , 0.93 s,
3H
1 8.81 (s, 1 H), 7.78 (d, J = 8.4 Hz, 2H), 7.53 (m,
OK 1 H), 7.47 (d, J = 8.4
Hz, 2H), 6.90 (m, 1 H), 6.74 (m, 1 H), 6.59 (m,
1 H), 4.83 (d, J = 6.8
Hz, 1 H), 4.08 (m, 1 H), 3.20-3.40 (m, 2H), 2.70-3.00
(m, 3H), 2.35
br s, 3H , 1.65-2.15 m, 5H , 1.1.5-1.50 m, 5H ,
0.87 s, 3H
1 8.33 (d, J = 5.1 Hz, 1 H), 7.99 (dd, J = 4.8 and
OL 1.8 Hz, 1 H), 7.86
(d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 7.53
(m, 1 H), 6.96 (d,
J = 6.4 Hz, 1 H), 6.75-6.85 (m, 2H), 4.15 (m, 1
H), 3.45 (m, 1 H),
3.30 (m, 1 H), 3.02 (s, 3H), 2.99 (m, 2H), 2.79
(m, 1 H), 2.47 and
2.48 (s, 3H), 2.45 (m, 1 H), 2.25 and 2.26 (s, 3H),
1.65-2.15 (m,
5H , 1.15-1.55 m, 5H , 0.90 s, 3H
Example 11
I~
1 CH HsC
N
~N
O CH3
O Br PhB(OH)2 I
CBr4
PdCl2(PPh3)2
Br
~N~BoC PPh3 w
CH CN N~BOC THF/H20 I
3 Na2C03 ~ N Boc
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-61 -
I
I ~ _H2 ~ TFA I i
N_ Pd(OH)2
Boc ~ N Boc I ~ N~H
I 1 ) Ti(OiPr)4
N-BOC-4-Piperidone I j N CN
-'-- Ex. 11
N 2) Et2AICN
H ~N~BOC
1) N-Boc-4-piperidone (10 g, 50 mmol) and PPh3 (53 g, 200 mmol)
were taken up in CH3CN (100 ml). The solution was cooled to 0 °C and
CBr4 (33 g, 100 mmol) was added to the solution at 0 °C. The
solution was
stirred at 0 °C for 15 min. and at 25 °C for 2 h. Et20 (200 ml)
was added,
and the resulting mixture was filtered through a plug of Si02.
Concentration gave a yellow solid. Purification via flash chromatography
(9/1 hexanes/Et20, Si02) gave 10 g (56 %) of the di-bromo product as a
white solid.
2) A solution of the product of step 1 (1 g, 2.8 mmol), PhB(OH)2 (1.2 g,
9.9 mmol), PdCl2(PPh3)2 (197 mg, 0.28 mmol), and Na2C03 (897 mg, 8.5
mmol) were taken up in THF/H20 (4/1, 20 ml) and stirred at 65 °C under
N2
for 24 h. The solution was partitioned between EtOAc and H20, the
aqueous layer was extracted with EtOAc and the combined organic layers
were washed with brine and dried over Na2S04. Filtration and
concentration gave a dark brown oil. Purification via flash chromatography
(9/1 hexanes/Et20, Si02) gave 941 mg (96 %) of the desired product as a
white solid, m.p. = 152-153 °C.
3) A solution of the product of step 2 (500 mg, 1.4 mmol) and Pd(OH)2
on carbon (100 mg, 20 wt % Pd (dry basis), 50 wt % H20) were taken up in
CHgOH (20 ml) and shaken in a Parr apparatus under H2 (50 psi) for 15 h.
The mixture was filtered and concentrated to give 501 mg (99 %) of the
diphenylmethyl piperidine as a colorless oil.
4) TFA (1.4 ml) was added to a solution of the product of step 3 (500
mg, 1.4 mmol) in CH2C12 (15 ml). The solution was stirred at 25 °C for
23
h. The solution was concentrated and the residue partitioned between
CH2C12 and 1 N NaOH. The aqueous layer was extracted with CH2C12, the
combined organic layers were dried over Na2S04, filtered and
concentrated to obtain 349 mg (99 %) of the free amine as a yellow oil,
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-62-
m.p. (HCI) = decomp. above 220-230 °C. HRMS calc'd for C~$H22N (MH+):
252.1752, Found: 252.1751.
5) A solution of the product of step 4 (349 mg, 1.4 mmol), N-Boc-4-
piperidone 280 mg, 1.4 mmol), and Ti(OiPr)4 (0.42 ml, 1.4 mmol) were
taken up CH2C12 (15 ml) under N2. After stirring at 25 °C for 17 h,
Et2AICN
(2.8 mmol, 2.8 ml of 1.0 M in toluene) was added and the solution was
stirred an additional 18 h at 25 °C. The solution was quenched with
sat.
NaHC03, diluted with EtOAc and filtered through Celite. The aqueous
layer was extracted with EtOAc and the combined EtOAc layers were dried
over Na2S04. Filtration and concentration gave a yellow oil. Purification
via preparative layer chromatography (3/1 hexanes/EtOAc, Si02) gave 430
mg (67 %) of the desired product as an oil.
6) A solution of the product of step 5 (430 mg, 0.94 mmol) in THF (20
ml) was cooled to 0 °C under N2. CH3MgBr (1.6 ml of 3.0 M in Et20, 4.7
mmol) was added at 0 °C and the solution stirred at 25 °C for 19
h. The
reaction mixture was quenched with sat. NH4C1, diluted with CH2C12 and 1
N NaOH (check aqueous layer with pH paper, pH = 8-10). The layers were
separated and the aqueous layer extracted with CH2C12. The combined
organic layers were dried over Na2S04, filtered and concentrated to obtain
a yellow oil. Purification via flash chromatography (3/1 hexanes/EtOAc,
Si02) gave 275 mg (65 %) of the product as a yellow oil.
7) TFA (0.60 ml) was added to a solution of the product of step 6 (275
mg, 0.61 mmol) in CH2C12 (15 ml) and the solution was stirred at 25 °C
for
18 h. The solution was concentrated and the residue was partitioned
between CH2C12 and 1 N NaOH. The aqueous layer was extracted with
CH2C12, the combined organic layers were dried over Na2S04, filtered and
concentrated to obtain 209 mg (99 %) of thje amine as a yellow oil. HRMS
calc'd for C24H33N2 (MH+): 349.2644, Found: 349.2638.
8) A solution of the product of step 7 (50 mg, 0.14 mmol), 2.6-dimethyl-
benzoic acid (63 mg, 0.42 mmol), EDCI (54 mg, 0.28 mmol), HOBT (38 mg,
0.28 mmol), and iPr2NEt (0.10 ml) were taken up in CH2C12 (3 ml). The
solution was stirred at 25 °C for 18 h, then diluted with CH2C12 and
washed
with 1 N NaOH. The aqueous layer was extracted with CH2C12, the
combined organic layers were dried over Na2S04, and filtered and
concentrated to give a yellow oil. Purification via preparative thin-layer
chromatography (3/1 hexanes/EtOAc Si02) gave 47 mg (70 %) of the title
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-63-
compound as a colorless oil, m.p. (HCI salt) = 195-201 °C. HRMS calc'd
for C33H41 N2~ (MH+): 481.3219, Found: 481.3225.
Using similar procedures, compounds of the following structure were
prepared
I,
Y1 CH3
Rs ~ I N
~N~R2
O
whorcin R6 anri R2 ara ac CIPfII'1PCJ in the table:
R6 R2 HRMS
MH+ found (HCi salt)
11A H ~ 482.3156 20~-20~
H3C~CH3
~~N
11 B F3co- ~ 565.3069 2oa-2o9
H3C ~ CH3
11 C H ~' 482.3168 ~ g7_~ g2
H3C ~ NH2
11 D F3C0- ~ 567.2957 ~ 75-181
H3C~CH3
NON
11 E F3C0- ~' 582.2966
H3C ~ CH3
~~O
11 F F3C0- H30 I \ ~H3 566.3020 175-181
~N
Example 12
CF3
I
i ~ N ,N ~ (~)
~N w N
' I
O
H Br
NaH ~ ~ 1 ) Br2 w w
~N~Boc ~_ ~ i N. ~ i N.
diethyl benzy Boc 2) KOtBu Boc
phosphonate
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-64-
Br
Br Br
wr ~ TFA ~ ) Ti(OiPr)4
i ~ w N-BOC-4-Piperidone I ~ N CN
~~%~~N . i N ~
Boc H 2) Et2AICN ~N'BOC
Br Br
N CN MeMgBr I ~ \ N
~N' ~N~BOC
BOC
Br CF3
w w 4-CF3C6H4B(OH)2
I , N~ Pd(PPhs)a ~ I
N~BOC THF/H20
Na2C03. ~ N
CF3 CF3 N~BOC
H2
-- Ex. 12
I ~ ~ N Pd(OH)2 I w
i N
~N. + ~ IN.
BOC ( _ ) BOC
1 ) N-Boc-4-piperidone (10 g, 50 mmol) and diethyl benzylphosponate
(12.6g, 55 mmol) were taken up in dry THF (50 ml) under N2. NaH (2.4 g,
60 mmol, 60 wt % in oil dispersion) was added to the solution at 25 °C.
The resulting mixture was heated at reflux for 3.5 h. The solution was
partitioned between EtOAc and saturated NH4C1, the aqueous layer was
extracted with EtOAc and the combined EtOAc layers were washed with
brine and dried over MgS04. Filtration and concentration afforded a yellow
oil. Purification via flash chromatography (10/1 hexanes/Et20, Si02) gave
9.85 g (72 %) of the desired compound as a solid, m.p. = 63-65 °C.
2) Bromine (1 ml, 20 mmol; dissolved in 10 ml CH2C12) was added
dropwise to a CH2C12 (100 ml) solution of the product of step 1 (5.0 g, 18
mmol) at 0 °C. The solution was stirred at 0 °C for 15 min, then
concentrated under reduced pressure. The crude product was taken up in
tert-butanoI/THF (4/1, 100 ml), and KOtBu (4.1 g, 36 mmol) was added to
the solution in portions. The yellow mixture was stirred at 25 °C for
5h,
then concentrated under reduced pressure. The residue was partitioned
between EtOAc and saturated NH4C1, the aqueous layer was extracted
with EtOAc, and the combined EtOAc layers were washed with brine and
dried over MgS04. Filtration and concentration gave a yellow solid.
Purification via flash chromatography (7/1 hexanes/Et20, Si02) gave 5.2 g
(81 %) of the desired product as a yellow solid. m.p. = 80-83 °C.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-65-
3) TFA (5.9 ml) was added to a solution of the product of step 2 (2.1 g,
5.9 mmol) in CH2C12 (25 ml). The solution was stirred at 25 °C for 5 h,
concentrated and the residue was partitioned between CH2C12 and 1 N
NaOH. The aqueous layer was extracted with CH2C12 and the combined
organic layers were dried over Na2S04, filtered and concentrated to obtain
1.46 g (98 %) of the amine as an orange oil, m.p. (HCI salt) = decomp.
above 185-195 °C. HRMS calc'd for C~2H15BrN (MH+): 254.0367, Found:
254.0374.
4) A solution of the product of step 3 (1.4 g, 5.6 mmol), N-Boc-4-
piperidone (1.1 g, 5.6 mmol), and Ti(OiPr)4 (1.7 ml, 5.6 mmol) were taken
up in CH2C12 (30 ml) under N2. After stirring at 25 °C for 18 h,
Et2ALCN
(6.7 mmol, 6.7 ml, 1.0 M in toluene) was added to the solution and the
solution was stirred an additional 18 h at 25 °C. The solution was
quenched with sat. NaHC03, diluted with EtOAc and filtered through Celite.
The aqueous layer was extracted with EtOAc and the combined EtOAc
layers were dried over Na2S04. Filtration and concentration gave a yellow
oil. Purification via flash chromatography (3/1 hexanes/EtOAc, Si02) gave
2.0 g (78 %) of the desired product as an off-white solid.
5) A solution of the product of step 4 (2.0 g, 4.3 mmol) in THF (30 ml)
was cooled to 0 °C under N2. CH3MgBr (7.2 ml of 3.0 M in Et20, 21 mmol)
was added to the solution at 0 °C. The solution was warmed to 25
°C and
stirred at that temperature for 16 h. The reaction mixture was quenched
with sat. NH4C1 and diluted with CH2C12 and 1 N NaOH (check aqueous
layer with pH paper, pH = 8-10). The layers were separated, the aqueous
layer was extracted with CH2C12 and the combined organic layers were
dried over Na2S04. Filtration and concentration gave a yellow oil.
Purification via flash chromatography (3/1 hexanes/EtOAc, Si02) gave 1.56
g (82 %) of the desired product as a yellow oil.
6) A solution of the product of step 5 (300 mg, 0.67 mmol),
4-CFgC6H4B(OH)2 (380 mg, 2 mmol), PdCl2(PPh3)2 (50 mg, 0.067 mmol),
and Na2C03 (210 mg, 2 mmol) were taken up THF/H20 (4/1, 15 ml) and
stirred at 65 °C under N2 for 18 h. The solution was partitioned
between
EtOAc and H20 and the aqueous layer was extracted with EtOAc. The
combined organic layers were washed with brine and dried over Na2S04.
Filtration and concentration gave a dark brown oil. Purification via flash
chromatography (4/1 hexanes/EtOAc, Si02) gave 229 mg (67 %) of the
desired product as a colorless oil.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-66-
7) A solution of the product of step 6 (229 mg, 0.45 mmol) and
Pd(OH)2 on carbon (200 mg, 20 wt % Pd (dry basis), 50 wt % H20) were
taken up in CH30H (35 ml) and shaken in a Parr apparatus under H2 (50
psi) for 20 h. The mixture was filtered and concentrated to obtain 232 mg
(100 %) of the (~)-product as a colorless foam. HRMS calc'd for
C3oH4o02N3 (MH+): 517.3042, Found: 517.3050.
8) TFA (0.45 ml) was added to a solution of the product of step 7 (235
mg, 0.45 mmol) in CH2C12 (15 ml). The solution was stirred at 25 °C for
24
h, then concentrated and the residue was partitioned between CH2C12 and
1 N NaOH. The aqueous layer was extracted with CH2C12, the combined
organic layers were dried over Na2S04, filtered and concentrated to obtain
146 mg (78 %) of the (~)-amine as a yellow oil.
9) A solution of the product of step 8 (102 mg, 0.25 mmol), 4,6-
dimethylpyrimidine-5-carboxylic acid (110 mg, 0.75 mmol), EDCI (96 mg,
0.50 mmol), HOBT (70 mg, 0.50 mmol), and iPr2NEt (0.17 ml) was taken
up in CH2C12 (3 ml). The solution was stirred at 25 °C for 18 h, then
diluted
with CH2C12 and washed with 1 N NaOH. The aqueous layer was
extracted with CH2C12, the combined organic layers were dried over
Na2S04, filtered and concentrated to obtain a yellow oil. Purification via
preparative thin-layer chromatography (1/1 acetone/hexanes Si02) gave
121 mg (88 %) of the title compound as a colorless oil, m.p. (HCI salt) _
186-191 °C. HRMS calc'd for Cg2HggN4OFg (MH+): 551.2998, Found:
551.3012.
The 4,6-dimethylpyrimidine-5-carboxylic acid used in step 9 was
made by the following process:
O O O C02Et C02H
1. Cs2C03 , formamidine ~ NaOH
2. CH OTf ~J~OCH3 ~
C02Et 3 C02Et acetate N ~ N N ~ N
Step 1: Ethyl diacetoacetate (93.4 g), Cs2COg (185 g) and CH3CN (550
ml) were mixed together, using an overhead mechanical stirrer. CH3CN
(50 ml) was added and the resulting mixture was cooled to 0°C. Methyl
trifluoromethane sulfonate (88.6 g) was added dropwise and after addition,
the cooling bath was removed. The mixture was stirred for 1 h at RT,
filtered, and the salts were washed with Et20 (2 X 50 ml). The organic
extracts were combined and Et20 (300 ml) was added. The resulting
mixture was filtered, the filter cake was washed with Et20 (2 X 100 ml), the
Et20 extracts were combined and evaporated to half volume. The solution
was cooled in an ice bath and washed once with cooled (0°C) 2 N NaOH
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-67-
(pH = 11 ). The Et20 layer was dried over MgS04, filtered and evaporated
to give the desired product as a yellow liquid (64.7 g) in 65% yield, which
was used directly in the next step.
St_ e~2: The product of step 1 (64.2 g), sodium ethoxide in ethanol
(commercial solution; 21 wt%; 113 g) and formamidine acetate (36.2 g)
were mixed together at RT. After refluxing for 4 h, the mixture was cooled
to RT, the resulting precipitate was filtered off and the ethanol was
removed under vacuum. The resulting liquid was partitioned between
water and CH2C12 and the aqueous layer was extracted with CH2C12 (3 x
150 ml). The CH2C12 extracts were dried over MgS04, filtered and
evaporated to give a dark crude liquid (50.7 g) which was purified by silica
gel chromatography (980 g; 4:1 hexanes:EtOAc as eluant). After
evaporation of the appropriate fractions, the desired product (28.5 g) was
isolated in 46% yield and used directly in the next step.
Step 3: The product of step 2 (28.1 g), NaOH (6.72 g), water (65 ml) and
EtOH (130 ml) were mixed together at RT and heated at reflux for 1 h. The
resulting solution was cooled to RT and the volatile materials were removed
in vacuo until a thick paste resulted. Water (20 ml) was added, the mixture
was cooled to 0°C and conc. HCI (14.3 ml) was added dropwise with
stirring. The resulting white precipitate was collected by filtration, washed
with ice water (2 X 10 ml) and air dried with suction for 30 min. The
resulting white solid was treated with toluene (2 x 20 ml), the solvent was
removed in vacuo at 50°C and then dried under vacuum (1 mm Hg) for 18
h. The desired product (14.9 g) was isolated as a white solid in 63% yield,
mp: 176-178°C. Elemental analysis of C~H$N202: calc'd C 55.26%, H
5.30%, N 18.41 %; found: C 55.13%, H 5.44%, N 18.18%.
A second crop of product was isolated by evaporation of the
aqueous filtrate (from above) to dryness and addition of water (20 ml). The
resulting mixture was stirred at RT for 5 min, cooled in an ice bath and the
precipitate formed was collected by filtration. The resulting solid was
washed with ice water (2 X 5 ml) and dried as described above to give the
product (4.68 g) as a cream colored solid to give a combined yield of 83%.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-68-
Example 13
~I
CI
~' 1
F3C0 ~ '.N N
~N ~ N
O
O
n-BuLi,
N CH3PPh3Br ~ I
N
CF30 ~NBoc ~CF30
~NBoc
1 ) 9-BBN I
CI
2) CI ~ I ~ I 1 ) TFA Ex. 13
N 2) standard
CF30 ~NBoc amidation
PdCl2dppf.Chi2Cl2
Cs2C03
Step1: To a suspension of methyltriphenylphosphonium bromide (1.89 g;
4.80 mmol) in anhydrous THF (15 ml) at -40 °C is added n-BuLi 2.5 N in
hexanes (2.12 ml; 5.3 mmol) via syringe. The reaction is allowed to warm
to 0 °C, stirred 30 min at this temperature, and a solution of the
product of
Example 6, step B-2 (2.24 g; 4.8 mmol) is added. The solution is then
allowed to warm to RT overnight, poured into CH2C12, and washed with
saturated NaHC03 then brine. The residue obtained after concentration of
the organic layer is purified by flash chromatography over silica gel (eluting
with CH2C12/EtOAc, 9:1 ) to afford 0.56 g (25%) of an oil.
Step 2: A solution of the product of step 1 (0.56 g; 1.2 mmol) and 9-BBN
0.5 N in THF (3 ml; 1.5 mmol) is refluxed 2 h under inert atmosphere. Part
of this solution (1.5 ml; 0.59 mmol of theoretical intermediate) is added to a
mixture of 1-chloro-3-iodobenzene (88 ~I; 0.71 mmol), PdCl2dppf.CH2Cl2
(19.8 mg), triphenylarsine (24.1 mg) and Cs2C03 (250 mg) in DMF (0.40 ml)
and water (80 ~I). The reaction is stirred 2 h at 60 °C and overnight
at RT,
poured into 5% aqueous NaHC03, and extracted with CH2C12. Combined
organic layers are dried over Na2S04, concentrated, and purified by
chromatography over silica gel (eluting with EtOAc/hexanes, 8:2) to provide
100 mg (29%) of an oil.
Step 3: The Boc-protecting group of the product of step 2 (100 mg; 0.17
mmol) was removed as in Example 2 to obtain the desired amine (70 mg;
86%). This amine (45 mg; 0.09 mmol) was coupled with 4,6-dimethyl-
pyrimidine-5-carboxylic acid following the conditions described in Example
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-69-
2 to obtain the title compound as a colorless oil (32 mg). 1 H-NMR (300
MHz, CDC13) S 8.93 (d, J = 3.8 Hz, 1 H), 6.90-7.10 (m, 5H), 6.88 (br s, 1 H),
6.71 (d, J = 7 Hz, 1 H), 4.20 (m, 1 H), 3.25-3.55 (m, 2H), 3.19 (m, 2H), 2.50-
3.10 (m, 5H), 2.47 and 2.48 (s, 3H), 2.42 and 2.43 (s, 3H), 1.70-2.20 (m,
5H), 1.20-1.65 (m, 5H), 0.92 (s, 3H); HRMS (MH+) 615.2722.
Using a similar procedure, the following compound was also
prepared:
F
1
F3C0 ~ ~N N
~N ~ N
13A HRMS (MH+) 599.3015
Example 14
F3C0 I ~ ~N'~ Enantiomers I and II
~N O
Br OCF3
w w 4-CF30C6H4B(OH)2
N PdCl2(PPh3)2
~N .
BOC THF/H20 ~ ~ I
Na2C03 ~ N
N~BOC
OCF3
(+)_1
H2 ~ ~ (Peak 1 =
Pd(OH)2 enantiomer I)
(-)-1
(Peak 2 =
_ ~N~ Chiral HPLC
(~) ~ BOC separation enantiomer II)
I~
As in example 11, steps 7-8 ~ ~ Y1
(+) _1 F3C0 ~ ~N
~N O
Enantiomer 1 R2
As in example 11, steps 7-8
Enantiomer 2
To prepare a compound wherein R2 is 2,6-dimethylphenyl:
1 ) A solution of the product of step 5 in example 12 (300 mg, 0.67
mmol), 4-CF30C6HQB(OH)2 (410 mg, 2 mmol), PdClz(PPh3)2 (50 mg, 0.067
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-70-
mmol), and Na2C03 (210 mg, 2 mmol) were taken up in THF/H20 (4/1, 15
ml) and stirred at 65 °C under NZ for 19 h. The solution was
partitioned
between EtOAc and H20, and the aqueous layer was extracted with EtOAc.
The combined organic layers were washed with brine and dried over
Na2S04. Filtration and concentration gave a dark brown oil. Purification via
flash chromatography (4/1 hexanes/EtzO, SiOz) gave 356 mg (100 %) of the
desired product as a yellow oil.
2) A solution of the product in step 1 (340 mg, 0.64 mmol) and Pd(OH)2
on carbon (300 mg, 20 wt % Pd (dry basis), 50 wt % Hz0) were taken up in
CH30H (35 ml) and shaken in a Parr apparatus under H2 (50 psi) for 18 h.
The mixture was filtered and concentrated to obtain 341 mg (100 %) of the
product, (~)-1, as a colorless foam.
3) The amine (~)-1 was resolved via chiral HPLC separation. The
conditions are as follows: CHIRALCEL~ OD'~' (5 cm x 30 cm); Hexane/
isopropyl alcohol/diethylamine 75/25/0.05) at 25° C; 254 nm detection.
The
retention times for peak 1, (+)-enantiomer, and peak 2, (-)-enantiomer were
3.8 and 4.9 minutes, respectively [CHIRALCEL~ ODT"' (hexane/ethanol/
diethylamine 90/10/0.1 ) 25° C at 254 nm]. Peak 1 and peak 2 are the
first
and second eluting peaks from the column, respectively. The enantiomers
(I and II) were deprotected (CHzCIz/TFA), and the free amine was coupled
to the 2,6-dimethylbenzoic acid using the conditions described in example
11, steps 7 and 8. The hydrochloride salts were obtained by taking the free
base up in EtOAc and triturating with 1 M HCI in Et20.
Data for the above compounds, 14A and 14B, and for additional
compounds made in a similar manner, are given in the following table. In
each case, the enantiomer designator I is derived from (+)-1 and the
enantiomer designated II is derived from (-)-1.
I ~ '. N
F3C0 ~ O
N
RI2
HRMS
Ex. Ar Enantiomerm. . HCI calc found
14A I 185-190 565.3042565.3050
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-71 -
14B II 175-180 565.3042565.3050
14C I 168-174 567.2947567.2951
~
I
NON
14D II 170-175 567.2947567.2957
~
I
NON
14 I 195-201 582.2944582.2944
E
i
~O-
14F II 180-185 582.2944582.2958
i ~
~O-
14G II 214-218 581.2991581.2984
OH
14H _ II 145-151 658.3257658.3251
-.
/ \
141 _ II 193-198 615.3010615.3016
~ CHF2
14J - NH~ II 195-200 651.3522651.3526
NHEt
Example 15
CH3
p 1
F3C ~ ~ N i
N
(~) O
Br 1 ) TFA Br
Br~ Br~N CN MeMgBr
N.Boc 2) N-Boc-4-piperidone
Ti(OiPr)4 ~N~gOC
3) Et2AICN
Me 4-CF3C6HQB(OH)2 Me
Br~ PdCl2(PPh3)2 ~ ~ H2
N I i N
~N, THF/H20 FsC Pd(OH)2
BOC ~N.
Na2C03 BOC
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-72-
Me 1 ) TFA
Ex. 15
F3C ~ i N 2) EDC,HOBT,
~N_ 2,6-dimethylbenzoic
(~) BOC acid
1 ) The dibromo-olefin (3.55 g, 10 mmol) and TFA (10 ml) were taken
up in CH2C12 and stirred at 25 °C for 20 h. The solution was
concentrated.
The residue was partitioned between CHZCIz and 1 N NaOH. The aqueous
layer was extracted with CHZC12. The combined organic layers were dried
(Na2S04). Filtration and concentration gave the 2.4 g (94 %) of the free
piperdine as a colorless oil. The free piperdine (2.41 g, 9.45 mmol) was
treated sequentially with (a) N-Boc-4-piperidone/Ti(OiPr)4, and (b) Et2AICN,
to give the cyano-amine as described in Step 5 of Example 11.
2) The product of Step 1 and MeMgBr (16 ml, 3.0 M in Et20) were
taken up in THF (30 ml) and stirred at 25 °C forl9 h. The solution was
quenched with 1 N NaOH and EtOAc. The mixture was filtered (Celite).
The aqueous layer was extracted with EtOAc, the combined EtOAc layers
were washed with brine and dried (Na2S04). Filtration and concentration
gave a yellow oil. Purification via flash chromatography (6/1 hexanes/
EtOAc, Si02) gave 2.54 g (69 % from the free piperidine) of the vinyl
bromide as a solid. m.p. (free base) 85-90 °C. HRMS (MH+) calcd. for
C,BH3ZOZNZBr , 387.1647; Found, 387.1638.
3) The product of Step 2 (200 mg, 0.52 mmol), 4-CF3CsH4B(OH)2 (344
mg, 1.8 mmol), PdClz(PPh3)2 (36 mg, 0.052 mmol), and Na2C03 (165 mg,
1.56 mmol) were taken up in THF/H20 (4/1, 10 ml) and heated at 75 °C
(oil
bath) for 21 hours. The solution was partitioned between EtOAc and H20.
The aqueous layer was extracted with EtOAc, the combined EtOAc layers
were washed with brine and dried (Na2S04). Filtration and concentration
gave a yellow oil. Purification via flash chromatography (3/1 to 1/1
hexanes/EtOAc, Si02) gave 210 mg (89 %) of the phenyl substitued olefin
as an oil. HRMS (MH') calcd. for CZSH3602N2F3 , 453.2729; Found,
453.2728.
4) The product of Step 3 was hydrogenated as described in Step 3 of
Example 11. The reduced product was deprotected and coupled to 2,6-
dimethyl benzoic acid as described in Example 11, steps 7- 8 to give the
title compound as a yellow oil (37 mg, 55%). m.p. (HCI salt) 130-140
°C.
HRMS (MH') calcd. for CZ9H380N2F3 , 487.2936; Found, 487.2928.
Using a similar procedure, the following compound was prepared:
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-73-
CH3
F3C0 ~ ~ N i
N
O 15A
m.p. (HCI salt) 135-145°C. HRMS (MH') calcd. for CZ9H3802N2F3 ,
503.2885;
Found, 503.2896.
The following assays can be used to determine the CCR5 inhibitory
and antagonistic activity of the compounds of the invention.
CCR5 Membrane Bindina Assay:
A high throughput screen utilizing a CCRS membrane binding assay
identifies inhibitors of RANTES binding. This assay utilizes membranes
prepared from NIH 3T3 cells expressing the human CCR5 chemokine receptor
which have the ability to bind to RANTES, a natural ligand for the receptor.
Using a 96-well plate format, membrane preparations are incubated with X251_
RANTES in the presence or absence of compound for one hour. Compounds
are serially diluted over a wide range of 0.001 ug/ml to 1 ug/ml and tested in
triplicates. Reaction cocktails are harvested through glass fiber filters, and
washed thoroughly. Total counts for replicates are averaged and data
reported as the concentration required to inhibit 50 percent of total ~251-
RANTES binding. Compounds with potent activity in the membrane binding
assay are further characterized in seconday cell-based HIV-1 entry and
replication assays.
HIV-1 Entry Assa~r:
Replication defective HIV-1 reporter virions are generated by
cotransfection of a plasmid encoding the NL4-3 strain of HIV-1 (which has
been modified by mutation of the envelope gene and introduction of a
luciferase reporter plasmid) along with a plasmid encoding one of several HIV-
1 envelope genes as described by Connor et al, Viroloav, 206 (1995), p. 935-
944. Following transfection of the two plasmids by calcium phosphate
precipitation, the viral supernatants are harvested on day 3 and a functional
viral titer determined. These stocks are then used to infect U87 cells stably
expressing CD4 and the chemokine receptor CCR5 which have been
preincubated with or without test compound. Infections are carried out for 2
hours at 37 °C, the cells washed and media replaced with fresh media
containing compound. The cells are incubated for 3 days, lysed and luciferase
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-74-
activity determined. Results are reported as the concentration of compound
required to inhibit 50% of the luciferase activity in the control cultures.
HIV-1 Replication Assa rL:
This assay uses primary peripheral blood mononuclear cells or the
stable U87-CCRS cell line to determine the effect of anti-CCR5 compounds to
block infection of primary HIV-1 strains. The primary lymphocytes are purified
from normal healthy donors and stimulated in vitro with PHA and IL-2 three
days prior to infection. Using a 96-well plate format, cells are pretreated
with
drug for 1 hour at 37 °C and subsequently infected with an M-tropic HIV-
1
isolates. Following infection, the cells are washed to remove residual
inoculum
and cultured in the presence of compound for 4 days. Culture supernatants
are harvested and viral replication measured by determination of viral p24
antigen concentration.
Calcium Flux Assay:
Cells expressing the HIV coreceptor CCR5 are loaded with calcium
sensitive dyes prior to addition of compound or the natural CCR5 ligand.
Compounds with agonist properties will induce a calcium flux signal in the
cell,
while CCRS antagonists are identified as compounds which do not induce
signaling by themselves but are capable of blocking signaling by the natural
ligand RANTES.
GTPYS Bindin4 Assay (secondary membrane binding assay):
A GTPyS binding assay measures receptor activation by CCR5 ligands.
This assay measures the binding of 35S labeled-GTP to receptor coupled G-
proteins that occurs as a result of receptor activation by an appropriate
ligand.
In this assay, the CCRS ligand, RANTES, is incubated with membranes from
CCR5 expressing cells and binding to the receptor activation (or binding) is
determined by assaying for bound 35S label. The assay quantitatively
determines if compounds exhibit agonist characteristics by inducing activation
of the receptor or alternatively antagonist properties by measuring inhibition
of
RANTES binding in a competitive or non-competitive fashion.
Chemotaxis Assay:
The chemotaxis assay is a functional assay which characterizes the
agonist vs. antagonist properties of the test compounds. The assay
measures the ability of a non-adherent murine cell line expressing human
CCR5 (BaF-550) to migrate across a membrane in response to either test
compounds or natural ligands (i.e., RANTES, MIP-1 (3). Cells migrate
across the permeable membrane towards compounds with agonist activity.
Compounds that are antagonists not only fail to induce chemotaxis, but are
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-75-
also capable of inhibiting cell migration in response to known CCRS
ligands.
The role of CC chemokine receptors such as CCR-5 receptors in
inflammatory conditions has been reported in such publications as
Immunolog~y Letters, 57, (1997), 117-120 (arthritis); Clinical & Experimental
Rheumatoloay, 17 (4) (1999), p. 419-425 (rheumatoid arthritis); Clinical &
Experimental Immunoloay, 117 (2) (1999), p.237-243 (atopic dermatitis);
International Journal of Immunopharmacoloay, 20 (11) (1998), p. 661-7
(psoriasis); Journal of AlIerqY & Clinical Immunoloay, 100 (6, Pt 2) (1997),
p. S52-5 (asthma); and Journal of Immunoloay, 159 (6) (1997), p. 2962-72
(allergies).
In the assay to determine inhibition of RANTES binding, compounds
of the invention range in activity from a Ki of 0.1 to 2000 nM, with preferred
compounds having a range of activity from 0.1 to 1000 nM, more preferably
0.1 to 500 nM, and most preferably 0.1 to 100 nM. The results for
preferred and representative compounds of formulas I and II in the test to
determine inhibition of RANTES binding are given in the table below. In the
table, "Ex. No." stands for "Example Number" and "nM" stands for
"nanomolar."
Ex. No. Ki (nM)
Inhibition of
RANTES bindin
1B 14
1J 1
2 9.6
2G 1.8
2S 17.9
2JJ 0.58
4B 0.5
4C 0.5
5L 7.9
5N 1.7
50 0.4
5Z 0.3
5AB 0.1
6V 0.8
7U 62.5
9D 588
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
-76-
For preparing pharmaceutical compositions from the CCR5
antagonist compounds described by this invention, inert, pharmaceutically
acceptable carriers can be either solid or liquid. Solid form preparations
include powders, tablets, dispersible granules, capsules, cachets and
suppositories. The powders and tablets may be comprised of from about 5
to about 95 percent active ingredient. Suitable solid carriers are known in
the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar or
lactose. Tablets, powders, cachets and capsules can be used as solid
dosage forms suitable for oral administration. Examples of
pharmaceutically acceptable carriers and methods of manufacture for
various compositions may be found in A. Gennaro (ed.), Remington's
Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co.,
Easton, Pennsylvania.
Liquid form preparations include solutions, suspensions and
emulsions. As an example may be mentioned water or water-propylene
glycol solutions for parenteral injection or addition of sweeteners and
opacifiers for oral solutions, suspensions and emulsions. Liquid form
preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions
and solids in powder form, which may be in combination with a
pharmaceutically acceptable carrier, such as an inert compressed gas, e.g.
nitrogen.
Also included are solid form preparations which are intended to be
converted, shortly before use, to liquid form preparations for either oral or
parenteral administration. Such liquid forms include solutions, suspensions
and emulsions.
The compounds of the invention may also be deliverable
transdermally. The transdermal compositions can take the form of creams,
lotions, aerosols and/or emulsions and can be included in a transdermal
patch of the matrix or reservoir type as are conventional in the art for this
purpose.
Preferably the compound is administered orally.
Preferably, the pharmaceutical preparation is in a unit dosage form.
In such form, the preparation is subdivided into suitably sized unit doses
containing appropriate quantities of the active component, e.g., an effective
amount to achieve the desired purpose.
CA 02371587 2001-10-24
WO 00/66559 PCT/US00/11633
_77_
The quantity of active compound in a unit dose of preparation may
be varied or adjusted from about 10 mg to about 500 mg, preferably from
about 25 mg to about 300 mg, more preferably from about 50 mg to about
250 mg, and most preferably from about 55 mg to about 200 mg, according
to the particular application.
The actual dosage of CCR5 compound employed may be varied
depending upon the requirements of the patient and the severity of the
condition being treated. Determination of the proper dosage regimen for a
particular situation is within the skill of the art. For convenience, the
total
daily dosage may be divided and administered in portions during the day as
required.
The amount and frequency of administration of the CCR5
compounds of the invention and/or the pharmaceutically acceptable salts
thereof will be regulated according to the judgment of the attending clinician
considering such factors as age, condition and size of the patient as well as
severity of the symptoms being treated. A typical recommended daily
dosage regimen for oral administration can range from about 100 mg/day
to about 300 mg/day, preferably 150 mg/day to 250 mg/day, more
preferably about 200 mg/day, in two to four divided doses.
The doses and dosage regimens of the NRTIs, NNRTIs, Pls and
other agents used in combination with the CCR5 antagonists will be
determined by the attending clinician inview of the approved doses and
dosage regimens in the package inserts or as set forth in the protocols,
taking into consideration the age, sex and condition of the patient and the
severity of the condition treated.
The goal of the HIV-1 therapy of the present invention is to reduce
the HIV-1-RNA viral load below the detectable limit. The "detectable limit of
HIV-1-RNA" in the context of the present invention means that there are
fewer than about 200 to fewer than about 50 copies of HIV-1-RNA per ml of
plasma of the patient as measured by quantitative, multi-cycle reverse
transcriptase PCR methodology. HIV-1-RNA is preferably measured in the
present invention by the methodology of Amplicor -1 Monitor 1.5 (available
from Roche Diagnsotics) or of Nuclisens HIV-1 QT -1.
While the present invention has been described in conjunction with
the specific embodiments set forth above, many alternatives, modifications
and variations thereof will be apparent to those of ordinary skill in the art.
All such alternatives, modifications and variations are intended to fall
within
the spirit and scope of the present invention.
